Drug-induced changes in P450 enzyme expression at the gene expression level: A new dimension to the analysis of drug–drug interactions

References

• Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, Touw DJ, Wieling J, Hekster YA, Burger DM. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clinical Pharmacology and Therapy 2005; 78(6)664–674
   PubMed Web of Science ®Google Scholar
• Abelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metabolism and Disposition 2000; 28(8)966–972
   PubMed Web of Science ®Google Scholar
• Afzelius L, Zamora I, Masimirembwa CM, Karlen A, Andersson TB, Mecucci S, Baroni M, Cruciani G. Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors. Journal of Medical Chemistry 2004; 47(4)907–914
   PubMed Web of Science ®Google Scholar
• Albers LJ, Ozdemir V, Marder SR, Raggi MA, Aravagiri M, Endrenyi L, Reist C. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: A prospective dose-adjusted drug interaction strategy. Journal of Clinical Psychopharmacology 2005; 25(2)170–174
   PubMedGoogle Scholar
• Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: Intraindividual variability and plasma concentration correlations. Journal of Clinical Pharmacology 2000; 40(1)58–66
   PubMedGoogle Scholar
• Allan LL, Sherr DH. Constitutive activation and environmental chemical induction of the aryl hydrocarbon receptor/transcription factor in activated human B lymphocytes. Molecular Pharmacology 2005; 67(5)1740–1750
   PubMedGoogle Scholar
• Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004; 63(10 Suppl. 4)S3–S8
   PubMed Web of Science ®Google Scholar
• Andersson TB, Bredberg E, Ericsson H, Sjoberg H. An evaluation of the in vitro metabolism data for predicting the clearance and drug–drug interaction potential of CYP2C9 substrates. Drug Metabolism and Disposition 2004; 32(7)715–721
   PubMed Web of Science ®Google Scholar
• Andrus MR. Oral anticoagulant drug interactions with statins: Case report of fluvastatin and review of the literature. Pharmacotherapy 2004; 24(2)285–290
   PubMed Web of Science ®Google Scholar
• Aouabdi S, Gibson G, Plant N. Transcriptional regulation of the PXR gene: Identification and characterization of a functional peroxisome proliferator-activated receptor alpha binding site within the proximal promoter of PXR. Drug Metabolism and Disposition 2006; 34(1)138–144
   PubMedGoogle Scholar
• Arimoto R, Prasad MA, Gifford EM. Development of CYP3A4 inhibition models: Comparisons of machine-learning techniques and molecular descriptors. Journal of Biomolecular Screening 2005; 10(3)197–205
   PubMedGoogle Scholar
• Aronson JK. Drug interactions — information, education, and the British National Formulary. British Journal of Clinical Pharmacology 2004; 57(4)473–486
   PubMedGoogle Scholar
• Asano T, Nishimoto K, Hayakawa M. Increased tacrolimus trough levels in association with severe diarrhea, a case report. Transplant Proceedings 2004; 36(7)2096–2097
   PubMed Web of Science ®Google Scholar
• Ascah KJ, Rock GA, Wells PS. Interaction between fenofibrate and warfarin. Annals of Pharmacotherapy 1998; 32(7–8)765–768
   PubMedGoogle Scholar
• Baba T, Mimura J, Nakamura N, Harada N, Yamamoto M, Morohashi K, Fujii-Kuriyama Y. Intrinsic function of the aryl hydrocarbon (dioxin) receptor as a key factor in female reproduction. Molecular Cell Biology 2005; 25(22)10040–10051
   PubMed Web of Science ®Google Scholar
• Bach MV, Coutts RT, Baker GB. Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica 1999; 29(7)719–732
   PubMed Web of Science ®Google Scholar
• Bachmann K, He Y, Sarver JG, Peng N. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica 2003; 33(3)265–276
   PubMed Web of Science ®Google Scholar
• Backlund M, Ingelman-Sundberg M. Different structural requirements of the ligand binding domain of the aryl hydrocarbon receptor for high- and low-affinity ligand binding and receptor activation. Molecular Pharmacology 2004; 65(2)416–425
   PubMedGoogle Scholar
• Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. American Journal of Cardiovascular Drugs 2004; 4(5)281–297
   PubMedGoogle Scholar
• Bapiro TE, Andersson TB, Otter C, Hasler JA, Masimirembwa CM. Cytochrome P450 1A1/2 induction by antiparasitic drugs: Dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. European Journal of Clinical Pharmacology 2002; 58(8)537–542
   PubMed Web of Science ®Google Scholar
• Bapiro TE, Egnell AC, Hasler JA, Masimirembwa CM. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metabolism and Disposition 2001; 29(1)30–35
   PubMed Web of Science ®Google Scholar
• Barclay TB, Peters JM, Sewer MB, Ferrari L, Gonzalez FJ, Morgan ET. Modulation of cytochrome P-450 gene expression in endotoxemic mice is tissue specific and peroxisome proliferator-activated receptor-alpha dependent. Journal of Pharmacology and Experimental Therapy 1999; 290(3)1250–1257
   PubMedGoogle Scholar
• Becquemont L, Mouajjah S, Escaffre O, Beaune P, Funck-Brentano C, Jaillon P. Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metabolism and Disposition 1999; 27(9)1068–1073
   PubMedGoogle Scholar
• Beers MH, Baran RW, Frenia K. Drugs and the elderly, Part 1: The problems facing managed care. American Journal of Management Care 2000; 6(12)1313–1320
   PubMedGoogle Scholar
• Bellosta S, Paoletti R, Corsini A. Safety of statins: Focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109(23 Suppl. 1)III50–III5
   PubMedGoogle Scholar
• Bergander L, Wahlstrom N, Alsberg T, Bergman J, Rannug A, Rannug U. Characterization of in vitro metabolites of the aryl hydrocarbon receptor ligand 6-formylindolo[3,2-b]carbazole by liquid chromatography-mass spectrometry and NMR. Drug Metabolism and Disposition 2003; 31(2)233–241
   PubMedGoogle Scholar
• Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine. Drug Metabolism and Disposition 2003; 31(3)289–293
   PubMed Web of Science ®Google Scholar
• Bhathena A, Lee C, Riddick DS. Suppression of cytochrome P450 2C11 by aromatic hydrocarbons: Mechanistic insights from studies of the 5′-flanking region of the CYP2C11 gene. Drug Metabolism and Disposition 2002; 30(12)1385–1392
   PubMedGoogle Scholar
• Bischoff E. Vardenafil preclinical trial data: Potency, pharmacodynamics, pharmacokinetics, and adverse events. International Journal of Impotence Research 2004; 16(Suppl. 1)S34–S37
   Google Scholar
• Bittinger MA, Nguyen LP, Bradfield CA. Aspartate aminotransferase generates proagonists of the aryl hydrocarbon receptor. Molecular Pharmacology 2003; 64(3)550–556
   PubMedGoogle Scholar
• Bolt HM. Rifampicin, a keystone inducer of drug metabolism: From Herbert Remmer. Drug Metabolism Reviews 2004; 36(3–4)497–509
   PubMed Web of Science ®Google Scholar
• Bonnabry P, Leemann T, Dayer P. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. European Journal of Clinical Pharmacology 1996; 49(4)305–308
   PubMed Web of Science ®Google Scholar
• Bonnet U. Moclobemide: Therapeutic use and clinical studies. CNS Drug Reviews 2003; 9(1)97–140
   PubMedGoogle Scholar
• Bort R, Mace K, Boobis A, Gomez-Lechon MJ, Pfeifer A, Castell J. Hepatic metabolism of diclofenac: Role of human CYP in the minor oxidative pathways. Biochemistry and Pharmacology 1999; 58(5)787–796
   PubMed Web of Science ®Google Scholar
• Brachtendorf L, Jetter A, Beckurts KT, Holscher AH, Fuhr U. Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacology and Toxicology 2002; 90(3)144–149
   PubMedGoogle Scholar
• Bramness JG, Skurtveit S, Fauske L, Grung M, Molven A, Morland J, Steen VM. Association between blood carisoprodol: Meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics 2003; 13(7)383–388
   Google Scholar
• Broderick PJ, Benjamin AB, Dennis LW. Caffeine and psychiatric medication interactions: A review. Journal of the Oklahoma State Medical Association 2005; 98(8)380–384
   PubMedGoogle Scholar
• Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie 2004; 59(1)5–12
   PubMed Web of Science ®Google Scholar
• Brosen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. European Neuropsychopharmacology 2001; 11(4)275–283
   PubMedGoogle Scholar
• Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, Avery MA, Fromm MF, Eichelbaum M. Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X-receptor and constitutive androstane receptor. Molecular Pharmacology 2005; 67(6)1954–1965
   PubMed Web of Science ®Google Scholar
• Carpenter SP, Lasker JM, Raucy JL. Expression, induction, and catalytic activity of the ethanol-inducible cytochrome P450 (CYP2E1) in human fetal liver and hepatocytes. Molecular Pharmacology 1996; 49(2)260–268
   PubMedGoogle Scholar
• Castberg I, Helle J, Aamo TO. Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline. Therapy and Drug Monitoring 2005; 27(5)680–682
   PubMed Web of Science ®Google Scholar
• Cazali N, Tran A, Treluyer JM, Rey E, d’Athis P, Vincent J, Pons G. Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. British Journal of Clinical Pharmacology 2003; 56(5)526–536
   PubMed Web of Science ®Google Scholar
• Cazzola M, Testi R, Matera MG. Clinical pharmacokinetics of salmeterol. Clinical Pharmacokinetics 2002; 41(1)19–30
   PubMed Web of Science ®Google Scholar
• Chalkiadis GA, Anderson BJ, Tay M, Bjorksten A, Kelly JJ. Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. British Journal of Anaesthesia 2005; 95(4)524–529
   PubMedGoogle Scholar
• Chan LM, Cooper AE, Dudley AL, Ford D, Hirst BH. P-glycoprotein potentiates CYP3A4-mediated drug disappearance during Caco-2 intestinal secretory detoxification. Journal of Drug Targetting 2004; 12(7)405–413
   PubMed Web of Science ®Google Scholar
• Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiology and Drug Safety 2005; 14(4)287
   PubMedGoogle Scholar
• Chang Y, Moody DE, McCance-Katz EF. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metabolism and Disposition 2006; 34(3)440–448
   PubMed Web of Science ®Google Scholar
• Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Brentano C. Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clinical Pharmacology and Therapy 2002; 72(5)514–523
   PubMedGoogle Scholar
• Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: Opening the X-files. Science 2001; 294(5548)1866–1870
   PubMed Web of Science ®Google Scholar
• Chen J, Halls SC, Alfaro JF, Zhou Z, Hu M. Potential beneficial metabolic interactions between tamoxifen and isoflavones via cytochrome P450-mediated pathways in female rat liver microsomes. Pharmacology Research 2004; 21(11)2095–2104
   PubMedGoogle Scholar
• Chen TG, Tai YT, Chang HC, Hong CT, Chen RM, Chen TL. Modulation of cytochrome P450-dependent monooxygenases in streptozotocin-induced diabetic hamster: II. Reverse role of insulin in P450 activity and defluorination. Acta Anaesthesiolgica Sinica 2000; 38(2)65–72
   PubMedGoogle Scholar
• Chen XP, Tan ZR, Huang SL, Huang Z, Ou-Yang DS, Zhou HH. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clinical Pharmacology and Therapy 2003; 73(3)264–271
   PubMed Web of Science ®Google Scholar
• Chen Y, Ferguson SS, Negishi M, Goldstein JA. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Molecular Pharmacology 2003; 64(2)316–324
   PubMedGoogle Scholar
• Cheng JW. Bosentan. Heart Disease 2003; 5(2)161–169
   PubMedGoogle Scholar
• Cheng ZN, Zhou HH. Contribution of genetic variations in estradiol biosynthesis and metabolism enzymes to osteoporosis. Acta Pharmacologica Sinica 2000; 21(7)587–590
   PubMedGoogle Scholar
• Cho JY, Yu KS, Jang IJ, Yang BH, Shin SG, Yim DS. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. British Journal of Clinical Pharmacology 2002; 53(4)393–397
   PubMed Web of Science ®Google Scholar
• Choi HJ, Choi JS. Effects of morin pretreatment on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem in rats. Archives of Pharmacology Research 2005; 28(8)970–976
   PubMedGoogle Scholar
• Chu R, Madison LD, Lin Y, Kopp P, Rao MS, Jameson JL, Reddy JK. Thyroid hormone (T3) inhibits ciprofibrate-induced transcription of genes encoding beta-oxidation enzymes: Cross talk between peroxisome proliferator and T3 signaling pathways. 1995; 92(25)11593–11597, Proceedings of the National Academy of Sciences, USA
   Google Scholar
• Chung WG, Park CS, Roh HK, Lee WK, Cha YN. Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Japan Journal of Pharmacology 2000; 84(2)213–220
   PubMedGoogle Scholar
• Ciusani E, Zullino DF, Eap CB, Brawand-Amey M, Brocard M, Baumann P. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: Pharmacokinetic and clinical aspects. Journal of Psychopharmacology 2004; 18(4)559–566
   PubMed Web of Science ®Google Scholar
• Coller JK. Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: An appraisal of in vitro studies. Clinical and Experimental Pharmacology and Physiology 2003; 30(11)845–848
   PubMed Web of Science ®Google Scholar
• Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ritonavir). Annals of Pharmacotherapy 2002; 36(7–8)1193–1203
   PubMedGoogle Scholar
• Corton JC, Fan LQ, Brown S, Anderson SP, Bocos C, Cattley RC, Mode A, Gustafsson JA. Down-regulation of cytochrome P450 2C family members and positive acute-phase response gene expression by peroxisome proliferator chemicals. Molecular Pharmacology 1998; 54(3)463–473
   PubMedGoogle Scholar
• Court MH, Duan SX, Hesse LM, Venkatakrishnan K, Greenblatt DJ. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 2001; 94(1)110–119
   PubMedGoogle Scholar
• Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R, Monnat M, Huttemann H, Baumann P, Eap CB. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clinical Pharmacology and Therapy 2005; 78(6)593–604
   PubMed Web of Science ®Google Scholar
• Cribb AE, Spielberg SP, Griffin GP. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metabolism and Disposition 1995; 23(3)406–414
   PubMed Web of Science ®Google Scholar
• Culm-Merdek KE, Von Moltke LL, Harmatz JS, Greenblatt DJ. Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. British Journal of Clinical Pharmacology 2005; 60(5)486–493
   PubMed Web of Science ®Google Scholar
• D’Arrigo C, Migliardi G, Santoro V, Morgante L, Muscatello MR, Ancione M, Spina E. Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. Pharmacology Research 2005; 52(6)497–501
   Google Scholar
• D'Souza DL, Dimmitt DC, Robbins DK, Nezamis J, Simms L, Koch KM. Effect of alosetron on the pharmacokinetics of fluoxetine. Journal of Clinical Pharmacology 2001; 41(4)455–458
   PubMedGoogle Scholar
• Dabrowska-Zamojcin E, Pawlik A, Domanski L, Rozanski J, Drozdzik M. Cyclosporine and sirolimus interaction in a kidney transplant patient. Transplant Proceedings 2005; 37(5)2317–2319
   PubMed Web of Science ®Google Scholar
• Dando TM, Perry CM. Aprepitant: A review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2004; 64(7)777–794
   PubMed Web of Science ®Google Scholar
• Daniel WA, Kot M, Wojcikowski J. Influence of classic and atypical neuroleptics on caffeine oxidation in rat liver microsomes. Polish Journal of Pharmacology 2003; 55(6)1055–1061
   PubMedGoogle Scholar
• Danish University Antidepressant Group (DUAG). Clomipramine dose–effect study in patients with depression: Clinical end points and pharmacokinetics. Danish University Antidepressant Group (DUAG). Clinical Pharmacology and Therapy 1999; 66(2)152–165
   PubMed Web of Science ®Google Scholar
• Davydov DR, Halpert JR, Renaud JP, Hui Bon Hoa G. Conformational heterogeneity of cytochrome P450 3A4 revealed by high pressure spectroscopy. Biochemistry and Biophysics Research Communication 2003; 312(1)121–130
   PubMedGoogle Scholar
• De Jonge ME, Huitema AD, Holtkamp MJ, Van Dam SM, Beijnen JH, Rodenhuis S. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemotherapy and Pharmacology 2005; 56(4)370–378
   PubMed Web of Science ®Google Scholar
• De Mey C, Althaus M, Ezan E, Retzow A. Erythromycin increases plasma concentrations of alpha-dihydroergocryptine in humans. Clinical Pharmacology and Therapy 2001; 70(2)142–148
   PubMedGoogle Scholar
• Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: A pharmacokinetic perspective. CNS Drugs 2001; 15(6)469–494
   PubMed Web of Science ®Google Scholar
• Desai PB, Nallani SC, Sane RS, Moore LB, Goodwin BJ, Buckley DJ, Buckley AR. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X-receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metabolism and Disposition 2002; 30(5)608–612
   PubMed Web of Science ®Google Scholar
• Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: Potent inhibition of CYP2C19 and CYP3A. Antimicrobial Agents and Chemotherapy 2001; 45(2)382–392
   PubMed Web of Science ®Google Scholar
• Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6. Journal of Pharmacology and Experimental Therapy 2004; 310(3)1062–1075
   PubMed Web of Science ®Google Scholar
• Desta Z, Wu GM, Morocho AM, Flockhart DA. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metabolism and Disposition 2002; 30(3)336–343
   PubMed Web of Science ®Google Scholar
• Desvergne B, Michalik L, Wahli W. Be fit or be sick: Peroxisome proliferator-activated receptors are down the road. Molecular Endocrinology 2004; 18(6)1321–1332
   PubMedGoogle Scholar
• DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L. Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. Journal of Clinical Psychopharmacology 2004; 24(1)4–10
   PubMed Web of Science ®Google Scholar
• Di Consiglio E, Meneguz A, Testai E. Organophosphorothionate pesticides inhibit the bioactivation of imipramine by human hepatic cytochrome P450s. Toxicology and Applied Pharmacology 2005; 15(205(3))237–246
   Google Scholar
• Dickins M. Induction of cytochromes P450. Current Topics in Medicine and Chemistry 2004; 4(16)1745–1766
   PubMedGoogle Scholar
• Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR, Tarbit MH. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metabolism and Disposition 1995; 23(11)1225–1230
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Kell S, Staskin D. Oxybutynin chloride: Alterations in drug delivery and improved therapeutic index. Expert Opinions in Pharmacotherapy 2002; 3(4)443–454
   PubMedGoogle Scholar
• Dong H, Haining RL, Thummel KE, Rettie AE, Nelson SD. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metabolism and Disposition 2000; 28(12)1397–1400
   PubMedGoogle Scholar
• Drolet B, Rousseau G, Daleau P, Cardinal R, Simard C, Turgeon J. Pimozide (Orap) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current in native cardiac myocytes. Journal of Cardiovascular and Pharmacology Therapy 2001; 6(3)255–260
   PubMedGoogle Scholar
• Dussault I, Yoo HD, Lin M, Wang E, Fan M, Batta AK, Salen G, Erickson SK, Forman BM. Identification of an endogenous ligand that activates pregnane X-receptor-mediated sterol clearance. 2003; 100(3)833–838, Proceedings of the National Academy of Sciences, USA
   Google Scholar
• Edsbacker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn. Clinical Pharmacokinetics 2004; 43(12)803–821
   PubMed Web of Science ®Google Scholar
• Ekins S, Bravi G, Ring BJ, Gillespie TA, Gillespie JS, Vandenbranden M, Wrighton SA, Wikel JH. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. Journal of Pharmacology and Experimental Therapy 1999; 288(1)21–29
   PubMed Web of Science ®Google Scholar
• Ekins S, Erickson JA. A pharmacophore for human pregnane X-receptor ligands. Drug Metabolism and Disposition 2002; 30(1)96–99
   PubMed Web of Science ®Google Scholar
• Ekins S, Vandenbranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV, Wrighton SA. Further characterization of the expression in liver and catalytic activity of CYP2B6. Journal of Pharmacology and Experimental Therapy 1998; 286(3)1253–1259
   PubMed Web of Science ®Google Scholar
• Ekstrom G, Gunnarsson UB. Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. Drug Metabolism and Disposition 1996; 24(9)955–961
   PubMed Web of Science ®Google Scholar
• Elmas T, Mavioglu O, Oztekin S, Elar Z, Guven H. The effect of propofol (anesthetic and inhibitor of CYP3A4) on serum lidocaine concentrations in smokers and chronic alcohol consumers. International Journal of Clinical Pharmacology and Therapy 2003; 41(4)182–184
   PubMedGoogle Scholar
• Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clinical Pharmacology and Therapy 1996; 59(6)613–623
   PubMed Web of Science ®Google Scholar
• Enggaard TP, Poulsen L, Arendt-Nielsen L, Brosen K, Ossig J, Sindrup SH. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesthetics and Analgesics 2006; 102(1)146–150
   PubMed Web of Science ®Google Scholar
• Eraly SA, Bush KT, Sampogna RV, Bhatnagar V, Nigam SK. The molecular pharmacology of organic anion transporters: from DNA to FDA? Molecular Pharmacology 2004; 65(3)479–487
   PubMed Web of Science ®Google Scholar
• Ernest II CS, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. Journal of Pharmacology and Experimental Therapy 2005; 312(2)583–591
   PubMed Web of Science ®Google Scholar
• Ernst ME, Kelly MW. Mibefradil, a pharmacologically distinct calcium antagonist. Pharmacotherapy 1998; 18(3)463–485
   PubMedGoogle Scholar
• Ernstgard L, Warholm M, Johanson G. Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity. British Journal of Clinical Pharmacology 2004; 58(2)190–200
   PubMedGoogle Scholar
• Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C, Yan B, Negishi M, LeCluyse EL. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metabolism and Disposition 2004; 32(3)348–358
   PubMed Web of Science ®Google Scholar
• Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone — metabolism, pharmacokinetics and interactions. Pharmacology Research 2004; 50(6)551–559
   Google Scholar
• Ferre P. The biology of peroxisome proliferator-activated receptors: Relationship with lipid metabolism and insulin sensitivity. Diabetes 2004; 53(Suppl. 1)S43–S50
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Morelli A, Pruzanski M, Pellicciari R. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. Journal of Pharmacology and Experimental Therapy 2005; 315(1)58–68
   PubMed Web of Science ®Google Scholar
• Fischer V, Vogels B, Maurer G, Tynes RE. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. Journal of Pharmacology and Experimental Therapy 1992; 260(3)1355–1360
   PubMedGoogle Scholar
• Fisman S, Reniers D, Diaz P. Erythromycin interaction with risperidone or clomipramine in an adolescent. Journal of Child and Adolescent Psychopharmacology 1996; 6(2)133–138
   PubMedGoogle Scholar
• Fuhr U, Kober S, Zaigler M, Mutschler E, Spahn-Langguth H. Rate-limiting biotransformation of triamterene is mediated by CYP1A2. International Journal of Clinical Pharmacology and Therapy 2005; 43(7)327–334
   PubMedGoogle Scholar
• Fuhr U, Muller-Peltzer H, Kern R, Lopez-Rojas P, Junemann M, Harder S, Staib AH. Effects of grapefruit juice and smoking on verapamil concentrations in steady state. European Journal of Clinical Pharmacology 2002; 58(1)45–53
   PubMed Web of Science ®Google Scholar
• Fuhr U, Strobl G, Manaut F, Anders EM, Sorgel F, Lopez-de-Brinas E, Chu DT, Pernet AG, Mahr G, Sanz F, et al. Quinolone antibacterial agents: Relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Molecular Pharmacology 1993; 43(2)191–199
   PubMedGoogle Scholar
• Fujii-Kuriyama Y, Mimura J. Molecular mechanisms of AhR functions in the regulation of cytochrome P450 genes. Biochemistry and Biophysics Research Communication 2005; 338(1)311–317
   PubMed Web of Science ®Google Scholar
• Funck-Brentano C, Boelle PY, Verstuyft C, Bornert C, Becquemont L, Poirier JM. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: Sources of variability and predictors of adverse effects in 419 healthy subjects. European Journal of Clinical Pharmacology 2005; 61(11)821–829
   PubMedGoogle Scholar
• Fung HB, Kirschenbaum HL, Hameed R. Amprenavir: A new human immunodeficiency virus type 1 protease inhibitor. Clinical Therapy 2000; 22(5)549–572
   PubMedGoogle Scholar
• Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metabolism and Pharmacokinetics 2005; 20(3)153–167
   PubMedGoogle Scholar
• Gambillara E, Laffitte E, Widmer N, Decosterd LA, Duchosal MA, Kovacsovics T, Panizzon RG. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia. Dermatology 2005; 211(4)363–365
   PubMedGoogle Scholar
• Ganter B, Tugendreich S, Pearson CI, Ayanoglu E, Baumhueter S, Bostian KA, Brady L, Browne LJ, Calvin JT, Day GJ, et al. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. Journal of Biotechnology 2005; 119(3)219–244
   PubMed Web of Science ®Google Scholar
• Garely AD, Burrows L. Benefit–risk assessment of tolterodine in the treatment of overactive bladder in adults. Drug Safety 2004; 27(13)1043–1057
   PubMedGoogle Scholar
• Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004; 16(1)36–44
   PubMed Web of Science ®Google Scholar
• Ghose R, Zimmerman TL, Thevananther S, Karpen SJ. Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation. Nucleic Receptors 2004; 2(1)4
   PubMedGoogle Scholar
• Giraud C, Tran A, Rey E, Vincent J, Treluyer JM, Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: Importance of CYP2C19. Drug Metabolism and Disposition 2004; 32(11)1279–1286
   PubMed Web of Science ®Google Scholar
• Gram LF, Guentert TW, Grange S, Vistisen K, Brosen K. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study. Clinical Pharmacology and Therapy 1995; 57(6)670–677
   PubMed Web of Science ®Google Scholar
• Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. British Journal of Clinical Pharmacology 2004; 57(3)349–353
   PubMedGoogle Scholar
• Greenblatt DJ, Von Moltke LL, Harmatz JS, Fogelman SM, Chen G, Graf JA, Mertzanis P, Byron S, Culm KE, Granda BW, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. Journal of Clinical Pharmacology 2003; 43(4)414–422
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: In vitro and clinical studies. Clinical Pharmacology and Therapy 2006; 79(1)125–133
   PubMedGoogle Scholar
• Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. British Journal of Clinical Pharmacology 2006; 61(1)58–69
   PubMedGoogle Scholar
• Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clinical Pharmacokinetics 2003; 42(14)1243–1285
   PubMed Web of Science ®Google Scholar
• Guglielminotti J, Maury E, Alzieu M, Delhotal Landes B, Becquemont L, Guidet B, Offenstadt G. Prolonged sedation requiring mechanical ventilation and continuous flumazenil infusion after routine doses of clorazepam for alcohol withdrawal syndrome. Intensive Care Medicine 1999; 25(12)1435–1436
   PubMedGoogle Scholar
• Guo GL, Lambert G, Negishi M, Ward JM, Brewer Jr HB, Kliewer SA, Gonzalez FJ, Sinal CJ. Complementary roles of farnesoid X-receptor, pregnane X-receptor, and constitutive androstane receptor in protection against bile acid toxicity. Journal of Biology and Chemistry 2003; 278(46)45062–45071
   PubMedGoogle Scholar
• Guo GL, Moffit JS, Nicol CJ, Ward JM, Aleksunes LA, Slitt AL, Kliewer SA, Manautou JE, Gonzalez FJ. Enhanced acetaminophen toxicity by activation of the pregnane X-receptor. Toxicology Science 2004; 82(2)374–380
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. Journal of the American Medical Association 2003; 289(9)1107–1116
   PubMed Web of Science ®Google Scholar
• Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D’Aquila RT, De Gruttola V, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: An Adult Aids Clinical Trials Group Study. Journal of Infectious Disease 2005; 192(11)1931–1942
   PubMed Web of Science ®Google Scholar
• Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: Review on drug interactions. Therapy and Drug Monitoring 2002; 24(1)91–103
   PubMed Web of Science ®Google Scholar
• Haduch A, Wojcikowski J, Daniel WA. The effect of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and newer antidepressant drugs on the activity and level of rat CYP3A. European Neuropsychopharmacology 2006; 16(3)178–186
   PubMedGoogle Scholar
• Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC. The interaction between St John. Clinical Pharmacology and Therapy 2003; 74(6)525–535
   PubMed Web of Science ®Google Scholar
• Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metabolism and Disposition 1998; 26(6)536–539
   PubMed Web of Science ®Google Scholar
• Handschin C, Meyer UA. Induction of drug metabolism: The role of nuclear receptors. Pharmacology Reviews 2003; 55(4)649–673
   PubMed Web of Science ®Google Scholar
• Hara Y, Nakajima M, Miyamoto KI, Yokoi T. Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: Prediction of in vivo drug interactions. Xenobiotica 2005; 35(6)549–560
   PubMed Web of Science ®Google Scholar
• Hartter S, Tybring G, Friedberg T, Weigmann H, Hiemke C. The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharmacology Research 2002; 19(7)1034–1037
   PubMed Web of Science ®Google Scholar
• He K, Woolf TF, Hollenberg PF. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). Journal of Pharmacology and Experimental Therapy 1999; 288(2)791–797
   PubMed Web of Science ®Google Scholar
• He N, Zhang WQ, Shockley D, Edeki T. Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes. European Journal of Clinical Pharmacology 2002; 57(12)847–851
   PubMedGoogle Scholar
• Heikinheimo O, Kekkonen R, Lahteenmaki P. The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception 2003; 68(6)421–426
   PubMed Web of Science ®Google Scholar
• Hemeryck A, De Vriendt C, Belpaire FM. Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: In vitro studies using human liver microsomes. Journal of Clinical Psychopharmacology 2000; 20(4)428–434
   PubMedGoogle Scholar
• Herman RJ. Drug interactions and the statins. Canadian Medical Association Journal 1999; 161(10)1281–1286
   Google Scholar
• Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000; 356(9247)2069–2070
   PubMed Web of Science ®Google Scholar
• Hersh EV, Moore PA. Drug interactions in dentistry: The importance of knowing your CYPs. Journal of the American Dental Association 2004; 135(3)298–311
   PubMedGoogle Scholar
• Hesse LM, Venkatakrishnan K, Court MH, Von Moltke LL, Duan SX, Shader RI, Greenblatt DJ. CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants. Drug Metabolism and Disposition 2000; 28(10)1176–1183
   PubMed Web of Science ®Google Scholar
• Hesse LM, Von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: Potential drug interactions with bupropion. Drug Metabolism and Disposition 2001; 29(2)100–102
   PubMed Web of Science ®Google Scholar
• Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno H, Koyano S, Katori N, Matsushima E, Uchiyama S, Tokunaga H, Kimura H, et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metabolism and Disposition 2005; 33(5)630–636
   PubMedGoogle Scholar
• Hidestrand M, Oscarson M, Salonen JS, Nyman L, Pelkonen O, Turpeinen M, Ingelman-Sundberg M. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson. Drug Metabolism and Disposition 2001; 29(11)1480–1484
   PubMed Web of Science ®Google Scholar
• Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metabolism and Disposition 2002; 30(7)853–858
   PubMed Web of Science ®Google Scholar
• Hoen PA, Bijsterbosch MK, Van Berkel TJ, Vermeulen NP, Commandeur JN. Midazolam is a phenobarbital-like cytochrome p450 inducer in rats. Journal of Pharmacology and Experimental Therapy 2001; 299(3)921–927
   PubMed Web of Science ®Google Scholar
• Hoetzel A, Leitz D, Schmidt R, Tritschler E, Bauer I, Loop T, Humar M, Geiger KK, Pannen BH. Mechanism of hepatic heme oxygenase-1 induction by isoflurane. Anesthesiology 2006; 104(1)101–109
   PubMedGoogle Scholar
• Holmgren P, Carlsson B, Zackrisson AL, Lindblom B, Dahl ML, Scordo MG, Druid H, Ahlner J. Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYD2D6 and CYP2C19. Journal of Analytical Toxicology 2004; 28(2)94–104
   PubMedGoogle Scholar
• Hong CC, Tang BK, Rao V, Agarwal S, Martin L, Tritchler D, Yaffe M, Boyd NF. Cytochrome P450 1A2 (CYP1A2) activity, mammographic density, and oxidative stress: A cross-sectional study. Breast Cancer Research 2004; 6(4)R338–R35
   Google Scholar
• Horsmans Y, Lannes D, Larrey D, Tinel M, Letteron P, Loeper J, Pessayre D. Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes. Xenobiotica 1991; 21(12)1559–1570
   PubMed Web of Science ®Google Scholar
• Howell SR, Shirley MA, Ulm EH. Effects of retinoid treatment of rats on hepatic microsomal metabolism and cytochromes P450. Correlation between retinoic acid receptor/retinoid x receptor selectivity and effects on metabolic enzymes. Drug Metabolism and Disposition 1998; 26(3)234–239
   PubMedGoogle Scholar
• Hruska MW, Amico JA, Langaee TY, Ferrell RE, Fitzgerald SM, Frye RF. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. British Journal of Clinical Pharmacology 2005; 59(1)70–79
   PubMedGoogle Scholar
• Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clinical Pharmacokinetics 1998; 35(4)275–291
   PubMed Web of Science ®Google Scholar
• Huang G, Elferink CJ. Multiple mechanisms are involved in Ah receptor-mediated cell cycle arrest. Molecular Pharmacology 2005; 67(1)88–96
   PubMedGoogle Scholar
• Huang W, Zhang J, Chua SS, Qatanani M, Han Y, Granata R, Moore DD. Induction of bilirubin clearance by the constitutive androstane receptor (CAR). 2003; 100(7)4156–4161, Proceedings of the National Academy of Sciences, USA
   Google Scholar
• Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, Chang FY, Lee SD. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37(4)924–930
   PubMed Web of Science ®Google Scholar
• Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochemistry and Pharmacology 2000; 59(8)961–972
   PubMed Web of Science ®Google Scholar
• Hummel MA, Locuson CW, Gannett PM, Rock DA, Mosher CM, Rettie AE, Tracy TS. CYP2C9 genotype-dependent effects on in vitro drug–drug interactions: Switching of benzbromarone effect from inhibition to activation in the CYP2C9. 3 variant. Molecular Pharmacology 2005; 68(3)644–651
   PubMedGoogle Scholar
• Huskey SW, Dean DC, Miller RR, Rasmusson GH, Chiu SH. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metabolism and Disposition 1995; 23(10)1126–1135
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Frye RF, Korzekwa KR, Branch RA, Huang SM, Tracy TS. Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. European Journal of Pharmacology Science 2001b; 14(1)47–52
   PubMedGoogle Scholar
• Hutzler JM, Hauer MJ, Tracy TS. Dapsone activation of CYP2C9-mediated metabolism: Evidence for activation of multiple substrates and a two-site model. Drug Metabolism and Disposition 2001a; 29(7)1029–1034
   PubMed Web of Science ®Google Scholar
• Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metabolism and Disposition 2003; 31(5)540–547
   PubMed Web of Science ®Google Scholar
• Iatsimirskaia E, Tulebaev S, Storozhuk E, Utkin I, Smith D, Gerber N, Koudriakova T. Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clinical Pharmacology and Therapy 1997; 61(5)554–562
   PubMed Web of Science ®Google Scholar
• Ide T, Shimano H, Yoshikawa T, Yahagi N, Amemiya-Kudo M, Matsuzaka T, Nakakuki M, Yatoh S, Iizuka Y, Tomita S, et al. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X-receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Molecular Endocrinology 2003; 17(7)1255–1267
   PubMedGoogle Scholar
• Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y, Funae Y. Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochemistry and Pharmacology 1996; 51(8)1041–1050
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics Journal 2005; 5(1)6–13
   PubMed Web of Science ®Google Scholar
• Ishiguro N, Senda C, Kishimoto W, Sakai K, Funae Y, Igarashi T. Identification of CYP3A4 as the predominant isoform responsible for the metabolism of ambroxol in human liver microsomes. Xenobiotica 2000; 30(1)71–80
   PubMed Web of Science ®Google Scholar
• Isohanni MH, Neuvonen PJ, Olkkola KT. Effect of itraconazole on the pharmacokinetics of inhaled lidocaine. Basic Clinical Pharmacology and Toxicology 2004; 95(3)120–123
   PubMedGoogle Scholar
• Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug–drug interactions from in vitro data. British Journal of Clinical Pharmacology 2004; 57(4)473–486
   PubMedGoogle Scholar
• Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics of pioglitazone. British Journal of Clinical Pharmacology 2006; 61(1)70–78
   PubMed Web of Science ®Google Scholar
• James MW, Hawkey CJ. Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract. British Journal of Clinical Pharmacology 2003; 56(2)146–155
   PubMedGoogle Scholar
• Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clinical Pharmacokinetics 2002; 41(10)719–739
   PubMed Web of Science ®Google Scholar
• Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clinical Therapy 2005; 27(11)1685–1695
   PubMed Web of Science ®Google Scholar
• Jeong EJ, Liu X, Jia X, Chen J, Hu M. Coupling of conjugating enzymes and efflux transporters: Impact on bioavailability and drug interactions. Current Drug Metabolism 2005; 6(5)455–468
   PubMed Web of Science ®Google Scholar
• Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. European Journal of Clinical Pharmacology 1996; 51(1)73–78
   PubMed Web of Science ®Google Scholar
• Johnson DR, Li CW, Chen LY, Ghosh JC, Chen JD. Regulation and binding of pregnane X-receptor by nuclear receptor corepressor silencing mediator of retinoid and thyroid hormone receptors (SMRT). Molecular Pharmacology 2006; 69(1)99–108
   PubMedGoogle Scholar
• Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. American Journal of Cardiology 2005; 95(1)120–122
   PubMed Web of Science ®Google Scholar
• Juge-Aubry CE, Gorla-Bajszczak A, Pernin A, Lemberger T, Wahli W, Burger AG, Meier CA. Peroxisome proliferator-activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X-receptor. Possible role of a leucine zipper-like heptad repeat. Journal of Biology and Chemistry 1995; 270(30)18117–18122
   PubMedGoogle Scholar
• Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clinical Pharmacology and Therapy 2005; 78(4)388–399
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Taylor TJ, Venkatakrishnan K, Isin EM. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metabolism and Disposition 2003; 31(3)243–249
   PubMedGoogle Scholar
• Kaminsky LS, deMorais SM, Faletto MB, Dunbar DA, Goldstein JA. Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe. Molecular Pharmacology 1993; 43(2)234–239
   PubMedGoogle Scholar
• Kanazawa S, Ohkubo T, Sugawara K. The effects of grapefruit juice on the pharmacokinetics of erythromycin. European Journal of Clinical Pharmacology 2001; 56(11)799–803
   PubMed Web of Science ®Google Scholar
• Kastelova A, Dimova S, Nemery B. Effects of propranolol on xenobiotic enzyme activities in rat type II pneumocytes and alveolar macrophages in vivo. Methods and Findings in Experimental and Clinical Pharmacology 2003; 25(10)797–802
   PubMedGoogle Scholar
• Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: Prediction of in vivo drug–drug interactions. European Journal of Clinical Pharmacology 2000; 55(11–12)843–852
   PubMed Web of Science ®Google Scholar
• Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: The Slone survey. Journal of the American Medical Association 2002; 287(3)337–344
   PubMed Web of Science ®Google Scholar
• Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clinical Pharmacokinetics 2000; 39(4)243–254
   PubMed Web of Science ®Google Scholar
• Ke S, Rabson AB, Germino JF, Gallo MA, Tian Y. Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide. Journal of Biology and Chemistry 2001; 276(43)39638–39644
   PubMed Web of Science ®Google Scholar
• Kearns GL, Robinson PK, Wilson JT, Wilson-Costello D, Knight GR, Ward RM, Van den Anker JN. Cisapride disposition in neonates and infants: In vivo reflection of cytochrome P450 3A4 ontogeny. Clinical Pharmacology and Therapy 2003; 74(4)312–325
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Hankins DC, Cox K. Clinical isoflurane metabolism by cytochrome P450 2E1. Anesthesiology 1999; 90(3)766–771
   PubMedGoogle Scholar
• Kharasch ED, Hankins DC, Thummel KE. Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology 1995; 82(3)689–699
   PubMed Web of Science ®Google Scholar
• Kim HJ, Choi JS. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. Biopharmacology and Drug Disposition 2005; 26(7)295–300
   PubMedGoogle Scholar
• Kim KA, Oh SO, Park PW, Park JY. Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. European Journal of Clinical Pharmacology 2005; 61(4)275–280
   PubMedGoogle Scholar
• Kim YC, Lee AK, Lee JH, Lee I, Lee DC, Kim SH, Kim SG, Lee MG. Pharmacokinetics of theophylline in diabetes mellitus rats: Induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. European Journal of Pharmacology Science 2005; 26(1)114–123
   PubMed Web of Science ®Google Scholar
• Kimura M, Yamazaki H, Fujieda M, Kiyotani K, Honda G, Saruwatari J, Nakagawa K, Ishizaki T, Kamataki T. Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metabolism and Disposition 2005; 33(9)1361–1366
   PubMedGoogle Scholar
• Kinobe RT, Parkinson OT, Mitchell DJ, Gillam EM. P450 2C18 Catalyzes the metabolic bioactivation of phenytoin. Chemical Research in Toxicology 2005; 18(12)1868–1875
   PubMedGoogle Scholar
• Kirchheiner J, Henckel HB, Meineke I, Roots I, Brockmoller J. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. Journal of Clinical Psychopharmacology 2004; 24(6)647–652
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics 2002; 12(7)571–580
   PubMedGoogle Scholar
• Kirchheiner J, Muller G, Meineke I, Wernecke KD, Roots I, Brockmoller J. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. Journal of Clinical Psychopharmacology 2003; 23(5)459–466
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J. Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: Clinical relevance. Clinical Pharmacokinetics 2005; 44(12)1209–1225
   PubMed Web of Science ®Google Scholar
• Kitamura A, Mizuno Y, Natsui K, Yabuki M, Komuro S, Kanamaru H. Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone. Biopharmacology and Drug Disposition 2005; 26(2)59–65
   PubMedGoogle Scholar
• Klees TM, Sheffels P, Thummel KE, Kharasch ED. Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology 2005; 102(3)550–556
   PubMedGoogle Scholar
• Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X-receptor: A key regulator of xenobiotic metabolism. Endocrine Reviews 2002; 23(5)687–702
   PubMed Web of Science ®Google Scholar
• Ko JW, Desta Z, Flockhart DA. Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. Drug Metabolism and Disposition 1998; 26(8)775–778
   PubMedGoogle Scholar
• Ko JW, Desta Z, Soukhova NV, Tracy T, Flockhart DA. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: Potent effect on CYP2C19 and CYP2D6. British Journal of Clinical Pharmacology 2000; 49(4)343–351
   PubMed Web of Science ®Google Scholar
• Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metabolism and Disposition 1997; 25(7)853–862
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Morita J, Chiba K, Wanibuchi A, Kimura M, Irie S, Urae A, Ishizaki T. Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans. Pharmacogenetics 2004a; 14(8)549–556
   PubMedGoogle Scholar
• Kobayashi K, Nakajima M, Chiba K, Yamamoto T, Tani M, Ishizaki T, Kuroiwa Y. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. British Journal of Clinical Pharmacology 1998; 45(4)361–368
   PubMedGoogle Scholar
• Kobayashi K, Sueyoshi T, Inoue K, Moore R, Negishi M. Cytoplasmic accumulation of the nuclear receptor CAR by a tetratricopeptide repeat protein in HepG2 cells. Molecular Pharmacology 2003; 64(5)1069–1075
   PubMedGoogle Scholar
• Kobayashi K, Yamagami S, Higuchi T, Hosokawa M, Chiba K. Key structural features of ligands for activation of human pregnane X-receptor. Drug Metabolism and Disposition 2004b; 32(4)468–472
   PubMed Web of Science ®Google Scholar
• Kocarek TA, Mercer-Haines NA. Squalestatin 1-inducible expression of rat CYP2B: Evidence that an endogenous isoprenoid is an activator of the constitutive androstane receptor. Molecular Pharmacology 2002; 62(5)1177–1186
   PubMedGoogle Scholar
• Kolilekas L, Anagnostopoulos GK, Lampaditis I, Eleftheriadis I. Potential interaction between telithromycin and warfarin. Annals of Pharmacotherapy 2004; 38(9)1424–1427
   PubMedGoogle Scholar
• Komoroski BJ, Parise RA, Egorin MJ, Strom SC, Venkataramanan R. Effect of the St. John. Clinical Cancer Research 2005; 11(19Pt1)6972
   PubMedGoogle Scholar
• Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS, Strom SC, Lehmann T, Ang CY, Cui YY, et al. Induction and inhibition of cytochromes P450 by the St. John. Drug Metabolism and Disposition 2004; 32(5)512–518
   PubMed Web of Science ®Google Scholar
• Korhonen LE, Rahnasto M, Mahonen NJ, Wittekindt C, Poso A, Juvonen RO, Raunio H. Predictive three-dimensional quantitative structure–activity relationship of cytochrome P450 1A2 inhibitors. Journal of Medical Chemistry 2005; 48(11)3808–3815
   PubMed Web of Science ®Google Scholar
• Korhonen T, Tolonen A, Uusitalo J, Lundgren S, Jalonen J, Laine K. The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. British Journal of Clinical Pharmacology 2005; 60(1)69–75
   PubMedGoogle Scholar
• Kortunay S, Bozkurt A, Basci NE, Brosen K, Kayaalp SO. Dose-dependent inhibition of the CYP2D6 catalyzed oxidation of sparteine by mepyramine in healthy volunteers. Pharmacology and Toxicology 2001; 89(6)331–334
   PubMedGoogle Scholar
• Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA, Adson DE. Inhibition of CYP2D6 activity by bupropion. Journal of Clinical Psychopharmacology 2005; 25(3)226–229
   PubMed Web of Science ®Google Scholar
• Krajka-Kuzniak V, Szaefer H, Baer-Dubowska W. Modulation of 3-methylcholanthrene-induced rat hepatic and renal cytochrome P450 and phase II enzymes by plant phenols: Protocatechuic and tannic acids. Toxicology Letters 2004; 152(2)117–126
   PubMedGoogle Scholar
• Krusekopf S, Roots I, Hildebrandt AG, Kleeberg U. Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+-ATPase inhibitors and other xenobiotics. Xenobiotica 2003; 33(2)107–118
   PubMed Web of Science ®Google Scholar
• Kubo M, Koue T, Inaba A, Takeda H, Maune H, Fukuda T, Azuma J. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. Drug Metabolism and Pharmacokinetics 2005; 20(1)55–64
   PubMedGoogle Scholar
• Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H. Trimethadione metabolism by human liver cytochrome P450: Evidence for the involvement of CYP2E1. Xenobiotica 1998; 28(11)1041–1047
   PubMed Web of Science ®Google Scholar
• Labbe L, Abolfathi Z, Lessard E, Pakdel H, Beaune P, Turgeon J. Role of specific cytochrome P450 enzymes in the N-oxidation of the antiarrhythmic agent mexiletine. Xenobiotica 2003; 33(1)13–25
   PubMed Web of Science ®Google Scholar
• Lakehal F, Wurden CJ, Kalhorn TF, Levy RH. Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19. Epilepsy Research 2002; 52(2)79–83
   PubMedGoogle Scholar
• Lakshmi VM, Zenser TV, Davis BB. Rat liver cytochrome P450 metabolism of N-acetylbenzidine and N,N'-diacetylbenzidine. Drug Metabolism and Disposition 1997; 25(4)481–488
   PubMedGoogle Scholar
• Lalovic B, Phillips B, Risler LL, Howald W, Shen DD. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metabolism and Disposition 2004; 32(4)447–454
   PubMed Web of Science ®Google Scholar
• Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J. CYP2D6 inhibition by selective serotonin reuptake inhibitors: Analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 2002; 22(8)1001–1006
   PubMed Web of Science ®Google Scholar
• Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, et al. Hepatic CYP2B6 expression: Gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. Journal of Pharmacology and Experimental Therapy 2003; 307(3)906–922
   PubMed Web of Science ®Google Scholar
• Landes N, Pfluger P, Kluth D, Birringer M, Ruhl R, Bol GF, Glatt H, Brigelius-Flohe R. Vitamin E activates gene expression via the pregnane X-receptor. Biochemistry and Pharmacology 2003; 65(2)269–273
   PubMed Web of Science ®Google Scholar
• Larsen JT, Brosen K. Consumption of charcoal-broiled meat as an experimental tool for discerning CYP1A2-mediated drug metabolism in vivo. Basic Clinical Pharmacology and Toxicology 2005; 97(3)141–148
   PubMed Web of Science ®Google Scholar
• Le Guellec C, Lacarelle B, Catalin J, Durand A. Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemotherapy and Pharmacology 1993; 32: 491–495
   PubMed Web of Science ®Google Scholar
• Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 2003; 144(8)3382–3398
   PubMed Web of Science ®Google Scholar
• Lee JH, Bae SK, Kwon JW, Kim WB, Lee MG. Effects of omeprazole or cola beverage on the pharmacokinetics of oral DA-8159, a new erectogenic, in rats. Biopharmacology and Drug Disposition 2005; 26(9)411–416
   PubMedGoogle Scholar
• Lejus C, Fautrel A, Malledant Y, Guillouzo A. Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochemistry and Pharmacology 2002a; 64(7)1151–1156
   PubMedGoogle Scholar
• Lejus C, Le Roux C, Legendre E, Renaudin M, Boiteau HL, Pinaud M. Fluoride excretion. in children after sevoflurane anaesthesia. British Journal of Anaesthesia 2002b; 89(5)693–696
   PubMedGoogle Scholar
• Lemaire G, Delescluse C, Pralavorio M, Ledirac N, Lesca P, Rahmani R. The role of protein tyrosine kinases in CYP1A1 induction by omeprazole and thiabendazole in rat hepatocytes. Life Sciences 2004; 74(18)2265–2278
   PubMed Web of Science ®Google Scholar
• Li AP, Lu C, Brent JA, Pham C, Fackett A, Ruegg CE, Silber PM. Cryopreserved human hepatocytes: Characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug–drug interaction potential. Chemico-Biological Interactions. 1999; 121(1)17–35
   Google Scholar
• Li D, Zimmerman TL, Thevananther S, Lee HY, Kurie JM, Karpen SJ. Interleukin-1 beta-mediated suppression of RXR: RAR transactivation of the Ntcp promoter is JNK-dependent. Journal of Biology and Chemistry 2002; 277(35)31416–31422
   PubMedGoogle Scholar
• Li J, Wen SY, Wang R, Chen K, Fang Y, Pei F, Wang SQ. Influence of cytochrom P450 CYP2C9 polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray. Yao Xue Xue Bao 2005; 40(8)695–699
   PubMedGoogle Scholar
• Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. European Journal of Clinical Pharmacology 2003; 59(5–6)429–442
   PubMed Web of Science ®Google Scholar
• Li Z, Iwai M, Wu L, Liu HW, Chen R, Jinno T, Suzuki J, Tsuda M, Gao XY, Okumura M, Cui TX, Horiuchi M. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension 2004; 44(5)758–763
   PubMedGoogle Scholar
• Lieber CS. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metabolism Reviews 2004; 36(3–4)511–529
   PubMed Web of Science ®Google Scholar
• Lin JC, Ito MK, Stolley SN, Morreale AP, Marcus DB. The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. Journal of Clinical Pharmacology 1999; 39(1)86–90
   PubMedGoogle Scholar
• Liu KH, Lee YM, Shon JH, Kim MJ, Lee SS, Yoon YR, Cha IJ, Shin JG. Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica 2004; 34(5)429–438
   PubMed Web of Science ®Google Scholar
• Liu S, Frye RF, Branch RA, Venkataramanan R, Fung JJ, Burckart GJ. Effect of age and postoperative time on cytochrome p450 enzyme activity following liver transplantation. Journal of Clinical Pharmacology 2005; 45(6)666–673
   PubMedGoogle Scholar
• Locuson II CW, Suzuki H, Rettie AE, Jones JP. Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors. Journal of Medical Chemistry 2004; 47(27)6768–6776
   PubMedGoogle Scholar
• Long ME, Bradshaw EL, Merz AL, Kerzic PJ. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing. Cancer Chemotherapy and Pharmacology 2005; 56(3)248–254
   PubMedGoogle Scholar
• Lu Y, Cederbaum AI. Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxicology Science 2006; 89(2)515–523
   PubMed Web of Science ®Google Scholar
• Ludwig E, Schmid J, Beschke K, Ebner T. Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5′-methylhydroxylation by quinidine and hydroquinidine in vitro. Journal of Pharmacology and Experimental Therapy 1999; 290(1)1–8
   PubMed Web of Science ®Google Scholar
• Luque CA, Rey JA. Sibutramine: A serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Annals of Pharmacotherapy 1999; 33(9)968–978
   PubMed Web of Science ®Google Scholar
• Luurila H, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. European Journal of Clinical Pharmacology 1998; 54(2)163–166
   PubMedGoogle Scholar
• Ma Y, Sachdeva K, Liu J, Song X, Li Y, Yang D, Deng R, Chichester CO, Yan B. Clofibrate and perfluorodecanoate both upregulate the expression of the pregnane X-receptor but oppositely affect its ligand-dependent induction on cytochrome P450 3A23. Biochemistry and Pharmacology 2005; 69(9)1363–1371
   PubMedGoogle Scholar
• Machinist JM, Mayer MD, Shet MS, Ferrero JL, Rodrigues AD. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metabolism and Disposition 1995; 23(10)1163–1174
   PubMedGoogle Scholar
• Madsen H, Rasmussen BB, Brosen K. Imipramine demethylation in vivo: Impact of CYP1A2, CYP2C19, and CYP3A4. Clinical Pharmacology and Therapy 1997; 61(3)319–324
   PubMedGoogle Scholar
• Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Molecular Pharmacology 2002; 62(3)638–646
   PubMed Web of Science ®Google Scholar
• Mancy A, Broto P, Dijols S, Dansette PM, Mansuy D. The substrate binding site of human liver cytochrome P450 2C9: An approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 1995; 34(33)10365–10375
   PubMed Web of Science ®Google Scholar
• Marechal JD, Yu J, Brown S, Kapelioukh I, Rankin EM, Wolf CR, Roberts GC, Paine MJ, Sutcliffe MJ. In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by co-medications commonly used by patients with cancer. Drug Metabolism and Disposition 2006; 34(4)534–538
   PubMed Web of Science ®Google Scholar
• Marino MR, Vachharajani NN. Drug interactions with irbesartan. Clinical Pharmacokinetics 2001; 40(8)605–614
   PubMed Web of Science ®Google Scholar
• Marks BD, Goossens TA, Braun HA, Ozers MS, Smith RW, Lebakken C, Trubetskoy OV. High-throughput screening assays for CYP2B6 metabolism and inhibition using fluorogenic vivid substrates. AAPS PharmScience 2003; 5(2)E18
   Google Scholar
• Martinez C, Albet C, Agundez JA, Herrero E, Carrillo JA, Marquez M, Benitez J, Ortiz JA. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clinical Pharmacology and Therapy 1999; 65(4)369–376
   PubMed Web of Science ®Google Scholar
• Massaro AM, Lenz KL. Aprepitant: A novel antiemetic for chemotherapy-induced nausea and vomiting. Annals of Pharmacotherapy 2005; 39(1)77–85
   PubMed Web of Science ®Google Scholar
• Masubuchi Y, Hosokawa S, Horie T, Suzuki T, Ohmori S, Kitada M, Narimatsu S. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metabolism and Disposition 1994; 22(6)909–915
   PubMed Web of Science ®Google Scholar
• Mathew NT, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: A comprehensive review. Headache 2003; 43(9)962–974
   PubMed Web of Science ®Google Scholar
• McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, Hesney M, Lines CR, Petty KJ, Deutsch PJ, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clinical Pharmacology and Therapy 2003; 74(1)17–24
   PubMed Web of Science ®Google Scholar
• McLaughlin LA, Paine MJ, Kemp CA, Marechal JD, Flanagan JU, Ward CJ, Sutcliffe MJ, Roberts GC, Wolf CR. Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding. Journal of Biology and Chemistry 2005; 280(46)38617–38624
   PubMedGoogle Scholar
• McLellan RA, Drobitch RK, Monshouwer M, Renton KW. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metabolism and Disposition 1996; 24(10)1134–1138
   PubMed Web of Science ®Google Scholar
• Meadowcroft AM, Williamson KM, Patterson JH, Hinderliter AL, Pieper JA. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. Journal of Clinical Pharmacology 1999; 39(4)418–424
   PubMedGoogle Scholar
• Merry C, Barry MG, Ryan M, Tjia JF, Hennessy M, Eagling VA, Mulcahy F, Back DJ. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS 1999; 13(15)F101–F107
   PubMed Web of Science ®Google Scholar
• Miao Z, Kamel A, Prakash C. Characterization of a novel metabolite intermediate of ziprasidone in hepatic cytosolic fractions of rat, dog, and human by ESI-MS/MS, hydrogen/deuterium exchange, and chemical derivatization. Drug Metabolism and Disposition 2005; 33(7)879–883
   PubMed Web of Science ®Google Scholar
• Micu AL, Miksys S, Sellers EM, Koop DR, Tyndale RF. Rat hepatic CYP2E1 is induced by very low nicotine doses: An investigation of induction, time course, dose response, and mechanism. Journal of Pharmacology and Experimental Therapy 2003; 306(3)941–947
   PubMedGoogle Scholar
• Mimura N, Kobayashi K, Nakamura Y, Shimada N, Hosokawa M, Chiba K. Metabolism of medroxyprogesterone acetate (MPA) via CYP enzymes in vitro and effect of MPA on bleeding time in female rats in dependence on CYP activity in vivo. Life Sciences 2003; 7(73(25))3201–3212
   Google Scholar
• Miura M, Kagaya H, Tada H, Sagae Y, Satoh S, Habuchi T, Suzuki T. Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. Xenobiotica 2005; 35(5)479–486
   PubMed Web of Science ®Google Scholar
• Miura M, Ohkubo T. In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions. Xenobiotica 2004; 34(11–12)1001–1011
   PubMed Web of Science ®Google Scholar
• Miyoshi Y, Taguchi T, Kim SJ, Tamaki Y, Noguchi S. Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers. Breast Cancer 2005; 12(1)11–15
   PubMedGoogle Scholar
• Monostory K, Hazai E, Vereczkey L. Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chemico-Biological Interactions. 2004; 147(3)331–340
   Google Scholar
• Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA. St. John's wort induces hepatic drug metabolism through activation of the pregnane X-receptor. 2000b; 97(13)7500–7502, Proceedings of the National Academy of Sciences, USA
   Google Scholar
• Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, Willson TM, et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X-receptor share xenobiotic and steroid ligands. Journal of Biology and Chemistry 2000a; 275(20)15122–15127
   PubMed Web of Science ®Google Scholar
• Moore TD, Nawarskas JJ, Anderson JR. Eplerenone: A selective aldosterone receptor antagonist for hypertension and heart failure. Heart Disease 2003; 5(5)354–363
   PubMedGoogle Scholar
• Morel Y, Barouki R. Repression of gene expression by oxidative stress. Biochemistry Journal 1999; 342(3)481–496
   PubMedGoogle Scholar
• Morgan ET. Regulation of cytochrome p450 by inflammatory mediators: Why and how? Drug Metabolism and Disposition. 2001; 29(3)207–212
   Google Scholar
• Morita K, Maeda Y, Masuda M, Kazusaka A, Imaoka S, Funae Y, Fujita S. Strain differences in CYP3A-mediated C-8 hydroxylation (1,3,7-trimethyluric acid formation) of caffeine in Wistar and Dark Agouti rats. Rapid metabolism of caffeine in debrisoquine poor metabolizer model rats. Biochemistry and Pharmacology 1998; 55(9)1405–1411
   PubMedGoogle Scholar
• Moubarak AS, Rosenkrans Jr CF, Johnson ZB. Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine. Veterinary and Human Toxicology 2003; 45(1)6–9
   PubMedGoogle Scholar
• Muangmoonchai R, Smirlis D, Wong SC, Edwards M, Phillips IR, Shephard EA. Xenobiotic induction of cytochrome P450 2B1 (CYP2B1) is mediated by the orphan nuclear receptor constitutive androstane receptor (CAR) and requires steroid co-activator 1 (SRC-1) and the transcription factor Sp1. Biochemistry Journal 2001; 355(1)71–78
   PubMedGoogle Scholar
• Nadin L, Murray M. Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. Biochemistry and Pharmacology 1999; 58(7)1201–1208
   PubMedGoogle Scholar
• Nagy J, Schipper HG, Koopmans RP, Butter JJ, Van Boxtel CJ, Kager PA. Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. American Journal of Tropical Medicine and Hygiene 2002; 66(3)260–263
   PubMedGoogle Scholar
• Nakajima M, Inoue T, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metabolism and Disposition 1998a; 26(3)261–266
   PubMed Web of Science ®Google Scholar
• Nakajima M, Kobayashi K, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y. Involvement of CYP1A2 in mexiletine metabolism. British Journal of Clinical Pharmacology 1998b; 46(1)55–62
   PubMed Web of Science ®Google Scholar
• Nakamura H, Ohtsuka T, Enomoto H, Hasegawa A, Kawana H, Kuriyama T, Ohmori S, Kitada M. Effect of levofloxacin on theophylline clearance during theophylline and clarithromycin combination therapy. Annals of Pharmacotherapy 2001; 35(6)691–693
   PubMedGoogle Scholar
• Nakamura K, Ariyoshi N, Iwatsubo T, Fukunaga Y, Higuchi S, Itoh K, Shimada N, Nagashima K, Yokoi T, Yamamoto K, et al. Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biology and Pharmacology Bulletin 2005; 28(5)882–885
   PubMed Web of Science ®Google Scholar
• Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M. Prediction of drug–drug interactions of zonisamide metabolism in humans from in vitro data. European Journal of Clinical Pharmacology 1998; 54(2)177–183
   PubMedGoogle Scholar
• Nakashima A, Kawashita H, Masuda N, Saxer C, Niina M, Nagae Y, Iwasaki K. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes. Xenobiotica 2005; 35(6)589–602
   PubMed Web of Science ®Google Scholar
• Nakatsuka A, Nagai M, Yabe H, Nishikawa N, Nomura T, Moritoyo H, Moritoyo T, Nomoto M. Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson. Journal of Pharmacology Science 2006; 100(1)59–64
   PubMed Web of Science ®Google Scholar
• Nallani SC, Glauser TA, Hariparsad N, Setchell K, Buckley DJ, Buckley AR, Desai PB. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X-receptor by topiramate. Epilepsia 2003; 44(12)1521–1528
   PubMedGoogle Scholar
• Narimatsu S, Mochida M, Ueno K, Horie T, Yamamoto S, Suzuki T. Induction of cytochrome P450 1A1 in mice by repeated oral administration of propranolol. Drug Metabolism and Pharmacokinetics 2002; 17(1)54–59
   PubMedGoogle Scholar
• Navas JM, Chana A, Herradon B, Segner H. Induction of cytochrome P4501A (CYP1A) by clotrimazole, a non-planar aromatic compound. Computational studies on structural features of clotrimazole and related imidazole derivatives. Life Sciences 2004; 76(6)699–714
   PubMedGoogle Scholar
• Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. Journal of Biology and Chemistry 2004; 279(23)23847–23850
   PubMed Web of Science ®Google Scholar
• Nielsen TL, Rasmussen BB, Flinois JP, Beaune P, Brosen K. In vitro metabolism of quinidine: The (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. Journal of Pharmacology and Experimental Therapy 1999; 289(1)31–37
   PubMedGoogle Scholar
• Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: Clinical relevance. Clinical Pharmacokinetics 2003; 42(9)819–850
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Juntti-Patinen L, Neuvonen M, Neuvonen PJ. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. British Journal of Clinical Pharmacology 2005; 60(2)208–217
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Kurata N, Sakurai E, Yasuhara H. Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. Journal of Pharmacology Science 2004; 96(3)293–300
   Google Scholar
• Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, Ohashi K. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertension Research 2005; 28(3)223–227
   PubMed Web of Science ®Google Scholar
• Niwa T, Shiraga T, Ishii I, Kagayama A, Takagi A. Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biology and Pharmacology Bulletin 2005a; 28(9)1711–1716
   PubMed Web of Science ®Google Scholar
• Niwa T, Shiraga T, Takagi A. Drug–drug interaction of antifungal drugs. Yakugaku Zasshi 2005b; 125(10)795–805
   PubMedGoogle Scholar
• Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: An in vitro study. Drug Metabolism and Disposition 2004; 33(2)262–270
   PubMedGoogle Scholar
• Oda Y, Mizutani K, Hase I, Nakamoto T, Hamaoka N, Asada A. Fentanyl inhibits metabolism of midazolam: Competitive inhibition of CYP3A4 in vitro. British Journal of Anaesthesia 1999; 82(6)900–903
   PubMedGoogle Scholar
• Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug–drug interactions. Drug Metabolism and Disposition 2006; 34(1)191–197
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Ueta A, Ando N, Ito T, Yamaguchi S, Mizuno K, Sumi S, Maeda T, Yamazaki D, Kurono Y, et al. Novel mutations in the cytochrome P450 2C19 gene: A pitfall of the PCR-RFLP method for identifying a common mutation. Journal of Human Genetics 2006; 15(2)118–123
   Google Scholar
• Oldham HG, Clarke SE. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(–)-carvedilol. Drug Metabolism and Disposition 1997; 25(8)970–977
   PubMed Web of Science ®Google Scholar
• Olesen OV, Linnet K. Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology 1997; 55(5)235–243
   PubMed Web of Science ®Google Scholar
• Olesen OV, Linnet K. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. British Journal of Clinical Pharmacology 2000; 50(6)563–571
   PubMed Web of Science ®Google Scholar
• Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M. Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996a; 26(7)681–693
   PubMed Web of Science ®Google Scholar
• Ono S, Hatanaka T, Miyazawa S, Tsutsui M, Aoyama T, Gonzalez FJ, Satoh T. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: Role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 1996b; 26(11)1155–1166
   PubMedGoogle Scholar
• Orans J, Teotico DG, Redinbo MR. The nuclear xenobiotic receptor pregnane X-receptor: Recent insights and new challenges. Molecular Endocrinology 2005; 19(12)2891–2900
   PubMed Web of Science ®Google Scholar
• Ostberg T, Bertilsson G, Jendeberg L, Berkenstam A, Uppenberg J. Identification of residues in the PXR ligand binding domain critical for species specific and constitutive activation. European Journal of Biochemistry 2002; 269(19)4896–4904
   PubMedGoogle Scholar
• Otani K, Tybring G, Mihara K, Yasui N, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K. Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients. European Journal of Clinical Pharmacology 1998; 53(5)347–349
   PubMedGoogle Scholar
• Otani K. Cytochrome P450 3A4 and Benzodiazepines. Seishin Shinkeigaku Zasshi 2003; 105(5)631–642
   PubMedGoogle Scholar
• Ou J, Tu H, Shan B, Luk A, DeBose-Boyd RA, Bashmakov Y, Goldstein JL, Brown MS. Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. 2001; 98(11)6027–6032, Proceedings of the National Academy of Sciences, USA
   Google Scholar
• Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone, and mirtazapine. Depression and Anxiety 1998; 7(Suppl. 1)24–32
   PubMedGoogle Scholar
• Ozdemir V, Fourie J, Busto U, Naranjo CA. Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence? Clinical Pharmacokinetics 1996; 31(5)372–385
   Google Scholar
• Park EJ, Cho HY, Lee YB. Effect of cimetidine and phenobarbital on metabolite kinetics of Omeprazole in rats. Archives of Pharmacology Research 2005; 28(10)1196–1202
   PubMedGoogle Scholar
• Park H, Lee S, Suh J. Structural and dynamical basis of broad substrate specificity, catalytic mechanism, and inhibition of cytochrome P450 3A4. Journal of the American Chemistry Society 2005; 127(39)13634–13642
   PubMed Web of Science ®Google Scholar
• Park JY, Kim KA, Kim SL. Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. Antimicrobial Agents and Chemotherapy 2003; 47(11)3464–3469
   PubMedGoogle Scholar
• Park-Wyllie LY, Antoniou T. Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: A case series. AIDS 2003; 17(4)638–640
   PubMedGoogle Scholar
• Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ. Dexamethasone induces pregnane X-receptor and retinoid X-receptor-alpha expression in human hepatocytes: Synergistic increase of CYP3A4 induction by pregnane X-receptor activators. Molecular Pharmacology 2000; 58(2)361–372
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: A tangle of networks of nuclear and steroid receptors. Biochimica et Biophysica Acta 2003; 1619(3)243–253
   PubMed Web of Science ®Google Scholar
• Payne VA, Chang YT, Loew GH. Homology modeling and substrate binding study of human CYP2C9 enzyme. Proteins 1999a; 37(2)176–190
   PubMedGoogle Scholar
• Payne VA, Chang YT, Loew GH. Homology modeling and substrate binding study of human CYP2C18 and CYP2C19 enzymes. Proteins 1999b; 37(2)204–217
   PubMedGoogle Scholar
• Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 1998; 28(12)1203–1253
   PubMed Web of Science ®Google Scholar
• Peng FC, Chang CC, Yang CY, Edwards RJ, Doehmer J. Territrems B and C metabolism in human liver microsomes: Major role of CYP3A4 and CYP3A5. Toxicology 2006; 218(2–3)172–185
   PubMedGoogle Scholar
• Pentiuk OO, Kachula SO, Herych OKh. Cytochrome P4502E1. Polymorphism, physiological function, regulation, and role in pathology. Ukr Biokhim Zh 2004; 76(5)16–28
   Google Scholar
• Perini JA, Vianna-Jorge R, Brogliato AR, Suarez-Kurtz G. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clinical Pharmacology and Therapy 2005; 78(4)362–369
   PubMedGoogle Scholar
• Pinto AG, Horlander J, Chalasani N, Hamman M, Asghar A, Kolwankar D, Hall SD. Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein. British Journal of Clinical Pharmacology 2005; 59(4)440–446
   PubMedGoogle Scholar
• Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. New England Journal of Medicine 2001; 344(13)984–996
   PubMed Web of Science ®Google Scholar
• Pocar P, Fischer B, Klonisch T, Hombach-Klonisch S. Molecular interactions of the aryl hydrocarbon receptor and its biological and toxicological relevance for reproduction. Reproduction 2005; 129(4)379–389
   PubMed Web of Science ®Google Scholar
• Polasek TM, Elliot DJ, Lewis BC, Miners JO. Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. Journal of Pharmacology and Experimental Therapy 2004; 311(3)996–1007
   PubMedGoogle Scholar
• Polasek TM, Miners JO. Quantitative prediction of macrolide drug–drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. European Journal of Clinical Pharmacology 2006; 17: 1–6
   Google Scholar
• Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. Journal of Clinical and Pharmacological Therapy 2000; 25(3)197–220
   PubMed Web of Science ®Google Scholar
• Preskorn SH. How drug–drug interactions can impact managed care. American Journal of Management Care 2004; 10(6 Suppl.)S186–S198
   Google Scholar
• Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. Journal of Psychiatry Neuroscience 2003; 28(2)99–112
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Richards KM, Qiu Y, Strong-Basalyga K, Miller A, Li C, Eisenhandler R, Carlini EJ. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharmacology Research 2005; 22(1)71–78
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metabolism and Disposition 2002; 30(11)1280–1287
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Kleinermans D, Love ER. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. British Journal of Clinical Pharmacology 2003; 56(Suppl. 1)62–68
   PubMedGoogle Scholar
• Qatanani M, Zhang J, Moore DD. Role of the constitutive androstane receptor in xenobiotic-induced thyroid hormone metabolism. Endocrinology 2005; 146(3)995–1002
   PubMed Web of Science ®Google Scholar
• Qin LQ, Wang PY, Wang Y, Kaneko T, Hoshi K, Sato A. Voglibose potentiates the hepatotoxicity of carbon tetrachloride and acetaminophen by inducing CYP2E1 in rats. Hepatology Research 2005; 33(1)50–56
   PubMedGoogle Scholar
• Racha JK, Zhao ZS, Olejnik N, Warner N, Chan R, Moore D, Satoh H. Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. Drug Metabolism and Pharmacokinetics 2003; 18(2)128–138
   PubMedGoogle Scholar
• Ramamoorthy Y, Yu AM, Suh N, Haining RL, Tyndale RF, Sellers EM. Reduced (±)-3,4-methylenedioxymethamphetamine (‘Ecstasy’) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochemistry and Pharmacology 2002; 63(12)2111–2119
   PubMed Web of Science ®Google Scholar
• Ramirez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metabolism and Disposition 2004; 32(9)930–936
   PubMedGoogle Scholar
• Rauschenbach R, Gieschen H, Husemann M, Salomon B, Hildebrand M. Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives. European Journal of Pharmacology 1995; 293(3)183–190
   PubMed Web of Science ®Google Scholar
• Raza H, Prabu SK, Robin MA, Avadhani NG. Elevated mitochondrial cytochrome P450 2E1 and glutathione S-transferase A4-4 in streptozotocin-induced diabetic rats: Tissue-specific variations and roles in oxidative stress. Diabetes 2004; 53(1)185–194
   PubMed Web of Science ®Google Scholar
• Regal KA, Kunze KL, Peter RM, Nelson SD. Oxidation of caffeine by CYP1A2: Isotope effects and metabolic switching. Drug Metabolism and Disposition 2005; 33(12)1837–1844
   PubMedGoogle Scholar
• Relling MV, Evans R, Dass C, Desiderio DM, Nemec J. Human cytochrome P450 metabolism of teniposide and etoposide. Journal of Pharmacology and Experimental Therapy 1992; 261(2)491–496
   PubMedGoogle Scholar
• Ren S, Yang JS, Kalhorn TF, Slattery JT. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Research 1997; 57(19)4229–4235
   PubMed Web of Science ®Google Scholar
• Renwick AB, Mistry H, Ball SE, Walters DG, Kao J, Lake BG. Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica 1998; 28(4)337–348
   PubMed Web of Science ®Google Scholar
• Richter T, Murdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, Zanger UM. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. Journal of Pharmacology and Experimental Therapy 2004; 308(1)189–197
   PubMed Web of Science ®Google Scholar
• Richter T, Schwab M, Eichelbaum M, Zanger UM. Inhibition of human CYP2B6 by N,N′,N′′-triethylenethiophosphoramide is irreversible and mechanism-based. Biochemistry and Pharmacology 2005; 69(3)517–524
   PubMedGoogle Scholar
• Riddick DS, Lee C, Bhathena A, Timsit YE, Cheng PY, Morgan ET, Prough RA, Ripp SL, Miller KK, Jahan A, et al. Transcriptional suppression of cytochrome P450 genes by endogenous and exogenous chemicals. Drug Metabolism and Disposition 2004; 32(4)367–375
   PubMedGoogle Scholar
• Ridtitid W, Wongnawa M, Mahatthanatrakul W, Raungsri N, Sunbhanich M. Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers. Journal of Clinical Pharmacology and Therapy 2005; 30(3)285–290
   PubMed Web of Science ®Google Scholar
• Rindone JP, Keng HC. Gemfibrozil–warfarin drug interaction resulting in profound hypoprothrombinemia. Chest 1998; 114(2)641–642
   PubMedGoogle Scholar
• Robertson Jr P, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clinical Pharmacokinetics 2003; 42(2)123–137
   PubMedGoogle Scholar
• Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: Are all cyclooxygenase inhibitors the same? Drug Metabolism and Disposition 2005; 33(11)1567–1575
   Google Scholar
• Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Decosterd L, Telenti A, Swiss HIV Cohort Study. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenetics and Genomics 2005; 15(1)1–5
   PubMedGoogle Scholar
• Ruhl R. Induction of PXR-mediated metabolism by beta-carotene Biochimica et Biophysica Acta 2005; 1740(2)162–169
   PubMedGoogle Scholar
• Sabia H, Sunkara G, Ligueros-Saylan M, Wang Y, Smith H, McLeod J, Prasad P. Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects. European Journal of Clinical Pharmacology 2004; 60(6)407–412
   PubMedGoogle Scholar
• Sadeque AJ, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. Journal of Pharmacology and Experimental Therapy 1997; 283(2)698–703
   PubMed Web of Science ®Google Scholar
• Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metabolism and Disposition 2003; 31(4)439–446
   PubMedGoogle Scholar
• Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin JS, Iwaki K, Nishiguchi K, Nakamura T, Okamura N, Okumura K. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-Mediated Transport. Pharmacology Research 2006; 23(3)506–512
   PubMedGoogle Scholar
• Salsali M, Holt A, Baker GB. Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell and Molecular Neurobiology 2004; 24(1)63–76
   PubMedGoogle Scholar
• Samer CF, Piguet V, Dayer P, Desmeules JA. Genetic polymorphism and drug interactions: Their importance in the treatment of pain. Canadian Journal of Anaesthesia 2005; 52(8)806–821
   PubMedGoogle Scholar
• Sanderink GJ, Bournique B, Stevens J, Petry M, Martinet M. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. Journal of Pharmacology and Experimental Therapy 1997; 282(3)1465–1472
   PubMed Web of Science ®Google Scholar
• Sandson N. Drug–drug interactions: The silent epidemic. Psychiatry Services 2005; 56(1)22–24
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharma-clinics medication of the month. Nebivolol (Nobiten) Revue Médicale de Liége 2001; 56(11)788–791
   PubMedGoogle Scholar
• Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: An update. Drug Safety 2005; 28(7)601–631
   PubMed Web of Science ®Google Scholar
• Schoedel KA, Sellers EM, Tyndale RF. Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochemistry and Pharmacology 2001; 62(8)1025–1036
   PubMed Web of Science ®Google Scholar
• Scordo MG, Spina E, Dahl ML, Gatti G, Perucca E. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clinical Pharmacology and Toxicology 2005; 97(5)296–301
   PubMed Web of Science ®Google Scholar
• Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clinical Pharmacokinetics 2001; 40(4)263–281
   PubMed Web of Science ®Google Scholar
• Seree EJ, Pisano PJ, Placidi M, Rahmani R, Barra YA. Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundamentals in Clinical Pharmacology 1993; 7: 69–75
   PubMed Web of Science ®Google Scholar
• Sharma A, Hamelin BA. Classic histamine H1 receptor antagonists: A critical review of their metabolic and pharmacokinetic fate from a bird. Current Drug Metabolism 2003; 4(2)105–129
   PubMed Web of Science ®Google Scholar
• Shayeganpour A, El-Kadi AO, Brocks DR. Determination of the enzyme(s) involved in the metabolism of amiodarone in liver and intestine of rat: The contribution of cytochrome P450 3A isoforms. Drug Metabolism and Disposition 2006; 34(1)43–50
   PubMedGoogle Scholar
• Shenoy SD, Spencer TA, Mercer-Haines NA, Abdolalipour M, Wurster WL, Runge-Morris M, Kocarek TA. Induction of CYP3A by 2,3-oxidosqualene: Lanosterol cyclase inhibitors is mediated by an endogenous squalene metabolite in primary cultured rat hepatocytes. Molecular Pharmacology 2004; 65(5)1302–1312
   PubMedGoogle Scholar
• Shet MS, Fisher CW, Holmans PL, Estabrook RW. Human cytochrome P450 3A4: Enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. 1993; 90(24)11748–11752, Proceedings of the National Academy of Sciences, USA
   Google Scholar
• Shet MS, McPhaul M, Fisher CW, Stallings NR, Estabrook RW. Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metabolism and Disposition 1997; 25(11)1298–1303
   PubMed Web of Science ®Google Scholar
• Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clinical Pharmacokinetics 2005; 44(9)915–934
   PubMedGoogle Scholar
• Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6. Drug Metabolism and Disposition 1999; 27(9)1078–1084
   PubMed Web of Science ®Google Scholar
• Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1: SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil. Journal of Pharmacology and Experimental Therapy 2004; 311(1)228–236
   PubMed Web of Science ®Google Scholar
• Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clinical Pharmacokinetics 2005; 44(8)797–814
   PubMed Web of Science ®Google Scholar
• Sidhu JS, Liu F, Boyle SM, Omiecinski CJ. PI3K inhibitors reverse the suppressive actions of insulin on CYP2E1 expression by activating stress–response pathways in primary rat hepatocytes. Molecular Pharmacology 2001; 59(5)1138–1146
   PubMedGoogle Scholar
• Simard C, Michaud V, Gibbs B, Masse R, Lessard E, Turgeon J. Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica 2004; 34(11–12)1013–1023
   PubMed Web of Science ®Google Scholar
• Simonsen U. Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. International Journal of Impotence Research 2002; 14(3)178–188
   PubMedGoogle Scholar
• Simooya OO, Sijumbil G, Lennard MS, Tucker GT. Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. British Journal of Clinical Pharmacology 1998; 45(3)315–317
   PubMedGoogle Scholar
• Sonoda J, Chong LW, Downes M, Barish GD, Coulter S, Liddle C, Lee CH, Evans RM. Pregnane X-receptor prevents hepatorenal toxicity from cholesterol metabolites. 2005; 102(6)2198–2203, Proceedings of the National Academy of Sciences
   Google Scholar
• Spaldin V, Madden S, Pool WF, Woolf TF, Park BK. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. British Journal of Clinical Pharmacology 1994; 38(1)15–22
   PubMed Web of Science ®Google Scholar
• Spigset O, Axelsson S, Norstrom A, Hagg S, Dahlqvist R. The major fluvoxamine metabolite in urine is formed by CYP2D6. European Journal of Clinical Pharmacology 2001; 57(9)653–658
   PubMed Web of Science ®Google Scholar
• Squires EJ, Sueyoshi T, Negishi M. Cytoplasmic localization of pregnane X-receptor and ligand-dependent nuclear translocation in mouse liver. Journal of Biology and Chemistry 2004; 279(47)49307–49314
   PubMed Web of Science ®Google Scholar
• Sridar C, Kent UM, Notley LM, Gillam EM, Hollenberg PF. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. Journal of Pharmacology and Experimental Therapy 2002; 301(3)945–952
   PubMed Web of Science ®Google Scholar
• Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. 2005; 98(6)3369–3374, Proceedings of the National Academy of Sciences, USA
   Google Scholar
• Stedman CA, Liddle C, Coulter SA, Sonoda J, Alvarez JG, Moore DD, Evans RM, Downes M. Nuclear receptors constitutive androstane receptor and pregnane X-receptor ameliorate cholestatic liver injury. 2005; 102(6)2063–2068, Proceedings of the National Academy of Sciences, USA
   Google Scholar
• Stormer E, Von Moltke LL, Shader RI, Greenblatt DJ. Metabolism of the antidepressant mirtazapine in vitro: Contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metabolism and Disposition 2000; 28(10)1168–1175
   PubMed Web of Science ®Google Scholar
• Stresser DM, Broudy MI, Ho T, Cargill CE, Blanchard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, Erve JC, et al. Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible. Drug Metabolism and Disposition 2004; 32(1)105–112
   PubMed Web of Science ®Google Scholar
• Stupans L, Tan HW, Kirlich A, Tuck K, Hayball P, Murray M. Inhibition of CYP3A-mediated oxidation in human hepatic microsomes by the dietary derived complex phenol, gallic acid. Journal of Pharmaceutics and Pharmacology 2002; 54(2)269–275
   PubMedGoogle Scholar
• Sutton D, Butler AM, Nadin L, Murray M. Role of CYP3A4 in human hepatic diltiazem N-demethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites. Journal of Pharmacology and Experimental Therapy 1997; 282(1)294–300
   PubMed Web of Science ®Google Scholar
• Suzuki A, Iida I, Hirota M, Akimoto M, Higuchi S, Suwa T, Tani M, Ishizaki T, Chiba K. CYP isoforms involved in the metabolism of clarithromycin in vitro: Comparison between the identification from disappearance rate and that from formation rate of metabolites. Drug Metabolism and Pharmacokinetics 2003; 18(2)104–113
   PubMedGoogle Scholar
• Suzuki S, Kurata N, Nishimura Y, Yasuhara H, Satoh T. Effects of imidazole antimycotics on the liver microsomal cytochrome P450 isoforms in rats: Comparison of in vitro and ex vivo studies. European Journal of Drug Metabolism and Pharmacokinetics 2000; 25(2)121–126
   PubMedGoogle Scholar
• Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, McKillop D, Wild MJ. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clinical Pharmacokinetics 2005; 44(10)1067–1081
   PubMed Web of Science ®Google Scholar
• Swales K, Negishi M. CAR, driving into the future. Molecular Endocrinology 2004; 18(7)1589–1598
   PubMedGoogle Scholar
• Szewczuk-Boguslawska M, Kiejna A, Beszlej JA, Orzechowska-Juzwenko K, Milejski P. Doxepin inhibits CYP2D6 activity in vivo. Polish Journal of Pharmacology 2004; 56(4)491–494
   PubMedGoogle Scholar
• Sztajnkrycer MD, Otten EJ, Bond GR, Lindsell CJ, Goetz RJ. Mitigation of pennyroyal oil hepatotoxicity in the mouse. Academy of Emergency Medicine 2003; 10(10)1024–1028
   PubMedGoogle Scholar
• Szutowski MM, Zalewska K, Jadczak M, Marek M. In vivo effect of diallyl sulfide and cimetidine on phenacetin metabolism and bioavailability in rat. Acta Biochimica Polonica 2002; 49(1)249–256
   PubMedGoogle Scholar
• Tanaka E. Clinically significant pharmacokinetic drug interactions with benzodiazepines. Journal of Clinical and Pharmacological Therapy 1999; 24(5)347–355
   PubMedGoogle Scholar
• Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesthetics and Analgesics 1996; 82(1)167–172
   PubMed Web of Science ®Google Scholar
• Tateishi T, Kumai T, Watanabe M, Tanaka M, Kobayashi S. A comparison of the effect of five phenothiazines on hepatic CYP isoenzymes in rats. Pharmacology and Toxicology 1999; 85(5)252–256
   PubMedGoogle Scholar
• Tateishi T, Watanabe M, Nakura H, Tanaka M, Kumai T, Aoki T, Kobayashi S. A comparison of the inhibitory effects of four volatile anaesthetics on the metabolism of chlorzoxazone, a substrate for CYP2E1, in rabbits. Acta Anaesthesiologica Scandinavica 1998; 42(9)1028–1032
   PubMedGoogle Scholar
• Teng S, Piquette-Miller M. The involvement of the pregnane X-receptor in hepatic gene regulation during inflammation in mice. Journal of Pharmacology and Experimental Therapy 2005; 312(2)841–848
   PubMed Web of Science ®Google Scholar
• Timsit YE, Riddick DS. Interference with growth hormone stimulation of hepatic cytochrome P4502C11 expression in hypophysectomized male rats by 3-methylcholanthrene. Toxicology and Applied Pharmacology 2000; 163(2)105–114
   PubMedGoogle Scholar
• Tinel M, Elkahwaji J, Robin MA, Fardel N, Descatoire V, Haouzi D, Berson A, Pessayre D. Interleukin-2 overexpresses c-myc and down-regulates cytochrome P-450 in rat hepatocytes. Journal of Pharmacology and Experimental Therapy 1999; 289(2)649–655
   PubMed Web of Science ®Google Scholar
• Tjon JA, Riemann LE. Treatment of intermittent claudication with pentoxifylline and cilostazol. American Journal of Health System Pharmacology 2001; 58(6)485–493
   PubMedGoogle Scholar
• Torimoto N, Ishii I, Hata M, Nakamura H, Imada H, Ariyoshi N, Ohmori S, Igarashi T, Kitada M. Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4. Biochemistry 2003; 42(51)15068–15077
   PubMedGoogle Scholar
• Tornio A, Pasanen MK, Laitila J, Neuvonen PJ, Backman JT. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clinical Pharmacology and Toxicology 2005; 97(2)104–108
   PubMedGoogle Scholar
• Totah RA, Rettie AE. Cytochrome P450 2C8: Substrates, inhibitors, pharmacogenetics, and clinical relevance. Clinical Pharmacology and Therapy 2005; 77(5)341–352
   PubMed Web of Science ®Google Scholar
• Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. British Journal of Clinical Pharmacology 1999; 47(5)545–552
   PubMed Web of Science ®Google Scholar
• Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR. Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. European Journal of Clinical Pharmacology 1997; 52(4)293–298
   PubMedGoogle Scholar
• Tran TH, Von Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS, Harmatz JS, Greenblatt DJ. Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metabolism and Disposition 2002; 30(12)1441–1445
   PubMedGoogle Scholar
• Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. European Journal of Clinical Pharmacology 1996; 50(3)209–215
   PubMed Web of Science ®Google Scholar
• Trauner M, Boyer JL. Bile salt transporters: Molecular characterization, function, and regulation. Physiology Reviews 2003; 83(2)633–671
   PubMed Web of Science ®Google Scholar
• Tucker AN, Tkaczuk KA, Lewis LM, Tomic D, Lim CK, Flaws JA. Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Letters 2005; 217(1)61–72
   PubMedGoogle Scholar
• Tugendreich S, Sagartz J, Pearson C, Jarnagin K, Kolaja K. NSAID-induced acute phase response is due to increased intestinal permeability and characterized by early and consistent alterations in hepatic gene expression. Toxicology and Pathology 2006; 34(2)168–179
   PubMedGoogle Scholar
• Tuo J, Loft S, Thomsen MS, Poulsen HE. Benzene-induced genotoxicity in mice in vivo detected by the alkaline comet assay: Reduction by CYP2E1 inhibition. Mutation Research 1996; 368(3–4)213–219
   PubMedGoogle Scholar
• Turnheim K. Drug interactions with antiepileptic agents. Wien Klin Wochenschr 2004; 116(4)112–118
   PubMedGoogle Scholar
• Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metabolism and Disposition 2004; 32(6)626–631
   PubMedGoogle Scholar
• Ushiama H, Echizen H, Nachi S, Ohnishi A. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Clinical Pharmacology and Therapy 2002; 72(1)33–43
   PubMed Web of Science ®Google Scholar
• Uttamsingh V, Lu C, Miwa G, Gan LS. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metabolism and Disposition 2005; 33(11)1723–1728
   PubMed Web of Science ®Google Scholar
• Van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, Sparreboom A, Gelderblom H. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clinical Cancer Research 2005; 11(21)7800–7806
   PubMed Web of Science ®Google Scholar
• Van Giersbergen PL, Treiber A, Clozel M, Bodin F, Dingemanse J. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin. receptor antagonist, and glyburide. Clinical Pharmacology and Therapy 2002; 71(4)253–262
   PubMedGoogle Scholar
• Van Schaik RH. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Investion into New Drugs 2005; 23(6)513–522
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Greenblatt DJ, Von Moltke LL, Schmider J, Harmatz JS, Shader RI. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: Dominance of CYP 2C19 and 3A4. Journal of Clinical Pharmacology 1998; 38(2)112–121
   PubMed Web of Science ®Google Scholar
• Vermes A, Vermes I. Genetic polymorphisms in cytochrome P450 enzymes: Effect on efficacy and tolerability of HMG-CoA reductase inhibitors. American Journal of Cardiovascular Drugs 2004; 4(4)247–255
   PubMedGoogle Scholar
• Von Moltke LL, Greenblatt DJ, Granda BW, Duan SX, Grassi JM, Venkatakrishnan K, Harmatz JS, Shader RI. Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations. British Journal of Clinical Pharmacology 1999; 48(1)89–97
   PubMedGoogle Scholar
• Von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS, Shader RI. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. Journal of Pharmaceutics and Pharmacology 1998; 50(9)997–1004
   PubMed Web of Science ®Google Scholar
• Voorman RL, Payne NA, Wienkers LC, Hauer MJ, Sanders PE. Interaction of delavirdine with human liver microsomal cytochrome P450: Inhibition of CYP2C9, CYP2C19, and CYP2D6. Drug Metabolism and Disposition 2001; 29(1)41–47
   PubMedGoogle Scholar
• Vormfelde SV, Engelhardt S, Zirk A, Meineke I, Tuchen F, Kirchheiner J, Brockmoller J. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clinical Pharmacology and Therapy 2004; 76(6)557–566
   PubMedGoogle Scholar
• Walisser JA, Glover E, Pande K, Liss AL, Bradfield CA. Aryl hydrocarbon receptor-dependent liver development and hepatotoxicity are mediated by different cell types. 2005; 102(49)17858–17863, Proceedings of the National Academy of Sciences, USA
   Google Scholar
• Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. Journal of Clinical Pharmacology 2005a; 45(1)68–78
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS, Gaman EA, Gleeson JP, Proctor WR. Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metabolism and Disposition 2005b; 33(3)413–418
   PubMed Web of Science ®Google Scholar
• Wan YJ, An D, Cai Y, Repa JJ, Hung-Po Chen T, Flores M, Postic C, Magnuson MA, Chen J, Chien KR, et al. Hepatocyte-specific mutation establishes retinoid X-receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver. Molecular Cell Biology 2000; 20(12)4436–4444
   PubMedGoogle Scholar
• Wang H, Faucette S, Moore R, Sueyoshi T, Negishi M, LeCluyse E. Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. Journal of Biology and Chemistry 2004; 279(28)29295–29301
   PubMed Web of Science ®Google Scholar
• Wang HX, Liu X, Xu CJ, Ma XC, Long JE, Li D. Induction of liver cytochrome P450 1A2 expression by flutamide in rats. Acta Pharmacologica Sinica 2005; 26(11)1382–1386
   PubMedGoogle Scholar
• Wang JF, Yang Y, Sullivan MF, Min J, Cai J, Zeldin DC, Xiao YF, Morgan JP. Induction of cardiac cytochrome p450 in cocaine-treated mice. Experiments in Biology and Medicine (Maywood) 2002; 227(3)182–188
   Google Scholar
• Wang RW, Liu L, Cheng H. Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metabolism and Disposition 1996; 24(7)786–791
   PubMed Web of Science ®Google Scholar
• Wang Y, Unadkat JD. Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. Biopharmacology and Drug Disposition 1999; 20(7)341–346
   PubMedGoogle Scholar
• Wang YH, Jones DR, Hall SD. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metabolism and Disposition 2005; 33(5)664–671
   PubMed Web of Science ®Google Scholar
• Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, Williams SP, Willson TM, Kliewer SA, Redinbo MR. The human nuclear xenobiotic receptor PXR: Structural determinants of directed promiscuity. Science 2001; 292(5525)2329–2333
   PubMed Web of Science ®Google Scholar
• Wei X, Dai R, Zhai S, Thummel KE, Friedman FK, Vestal RE. Inhibition of human liver cytochrome P-450 1A2 by the class IB antiarrhythmics mexiletine, lidocaine, and tocainide. Journal of Pharmacology and Experimental Therapy 1999; 289(2)853–858
   PubMedGoogle Scholar
• Wen X, Wang JS, Backman JT, Kivisto KT, Neuvonen PJ. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metabolism and Disposition 2001; 29(11)1359–1361
   PubMed Web of Science ®Google Scholar
• Wen X, Wang JS, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metabolism and Disposition 2002; 30(6)631–635
   PubMed Web of Science ®Google Scholar
• Werck-Reichhart D, Feyereisen R. Cytochromes P450: A success story. Genome Biology 2000; 1(6)3003.1–3003.9
   Google Scholar
• Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clinical Pharmacology and Therapy 2003; 74(2)130–137
   PubMed Web of Science ®Google Scholar
• White IN. Tamoxifen: Is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Current Drug Metabolism 2003; 4(3)223–239
   PubMedGoogle Scholar
• Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nature Reviews in Drug Discovery 2005; 4(10)825–833
   PubMed Web of Science ®Google Scholar
• Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. Drug–drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metabolism and Disposition 2004; 32(11)1201–1208
   PubMed Web of Science ®Google Scholar
• Wolf CR, Smith G. Cytochrome P450 CYP2D6. IARC Science Publications 1999; 148: 209–229
   PubMedGoogle Scholar
• Wrighton SA, Ring BJ. Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharmacology Research 1994; 11(6)921–924
   PubMedGoogle Scholar
• Wu D, Otton SV, Sproule BA, Busto U, Inaba T, Kalow W, Sellers EM. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. British Journal of Clinical Pharmacology 1993; 35(1)30–34
   PubMedGoogle Scholar
• Xiao L, Cui X, Madison V, White RE, Cheng KC. Insights from a three-dimensional model into ligand binding to constitutive active receptor. Drug Metabolism and Disposition 2002; 30(9)951–956
   PubMedGoogle Scholar
• Xie H, Griskevicius L, Stahle L, Hassan Z, Yasar U, Rane A, Broberg U, Kimby E, Hassan M. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. European Journal of Pharmacology Science 2006; 27(1)54–61
   PubMed Web of Science ®Google Scholar
• Xie W, Barwick JL, Simon CM, Pierce AM, Safe S, Blumberg B, Guzelian PS, Evans RM. Reciprocal activation of xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Development 2000; 14(23)3014–3023
   PubMed Web of Science ®Google Scholar
• Yamada M, Miyamura K, Fujiwara T, Yokoyama H, Tomiya Y, Ishizawa K, Harigae H, Kameoka J, Sasaki T. Imatinib mesylate in conjunction with allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome positive leukemias: Report of 4 cases. Tohoku Journal of Experimental Medicine 2004; 204(1)79–84
   PubMedGoogle Scholar
• Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. Journal of Clinical Oncology 2000; 18(11)2301–2308
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Suzuki A, Kohno Y. High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method. Xenobiotica 2004; 34(1)87–101
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Nakajima M, Fukami T, Sakai H, Nakamura A, Katoh M, Takamiya M, Aoki Y, Yokoi T. CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: Interindividual differences in these contributions. Drug Metabolism and Disposition 2005; 33(12)1811–1818
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shaw PM, Guengerich FP, Shimada T. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chemical Research in Toxicology 1998; 11(6)659–665
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shimada T. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica 1999; 29(3)231–241
   PubMed Web of Science ®Google Scholar
• Yamreudeewong W, DeBisschop M, Martin LG, Lower DL. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Safety 2003; 26(6)421–438
   PubMed Web of Science ®Google Scholar
• Yan Z, Caldwell GW. Metabolic assessment in liver microsomes by co-activating cytochrome P450s and UDP-glycosyltransferases. European Journal of Drug Metabolism and Pharmacokinetics 2003; 28(3)223–232
   PubMed Web of Science ®Google Scholar
• Yan Z, Li J, Huebert N, Caldwell GW, Du Y, Zhong H. Detection of a novel reactive metabolite of diclofenac: Evidence for CYP2C9-mediated bioactivation via arene oxides. Drug Metabolism and Disposition 2005; 33(6)706–713
   PubMedGoogle Scholar
• Yang TJ, Sai Y, Krausz KW, Gonzalez FJ, Gelboin HV. Inhibitory monoclonal antibodies to human cytochrome P450 1A2: Analysis of phenacetin O-deethylation in human liver. Pharmacogenetics 1998; 8(5)375–382
   PubMedGoogle Scholar
• Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S, Tateishi T. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. British Journal of Clinical Pharmacology 2004; 57(4)487–494
   PubMed Web of Science ®Google Scholar
• Yilmaz N, Erbagci AB, Aynacioglu AS. Cytochrome P4502C9 genotype in Southeast Anatolia and possible relation with some serum tumour markers and cytokines. Acta Biochimica Polonica 2001; 48(3)775–782
   PubMedGoogle Scholar
• Yoshii K, Kobayashi K, Tsumuji M, Tani M, Shimada N, Chiba K. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sciences 2000; 2: 175–184
   Google Scholar
• Yoshikawa T, Ide T, Shimano H, Yahagi N, Amemiya-Kudo M, Matsuzaka T, Yatoh S, Kitamine T, Okazaki H, Tamura Y, et al. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X-receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. Molecular Endocrinology 2003; 17(7)1240–1254
   PubMedGoogle Scholar
• Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers — N-desisopropylation is mediated mainly by CYP1A2. British Journal of Clinical Pharmacology 1995; 39(4)421–431
   PubMed Web of Science ®Google Scholar
• Youlten L. The effect of repeat dosing with cimetidine on the pharmacokinetics of intravenous granisetron in healthy volunteers. Journal of Pharmaceutics and Pharmacology 2004; 56(2)169–175
   PubMedGoogle Scholar
• Yu LS, Yao TW, Zeng S. In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan. Chemico-Biological Interactions 2003; 146(3)263–272
   Google Scholar
• Yue QY, Sawe J. Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. European Journal of Clinical Pharmacology 1997; 52(1)41–47
   PubMedGoogle Scholar
• Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Archives in Pharmacology 2004; 369(1)23–37
   PubMed Web of Science ®Google Scholar
• Zhang H, LeCulyse E, Liu L, Hu M, Matoney L, Zhu W, Yan B. Rat pregnane X-receptor: Molecular cloning, tissue distribution, and xenobiotic regulation. Archives of Biochemistry and Biophysics 1999; 368(1)14–22
   PubMedGoogle Scholar
• Zhang J, Huang W, Qatanani M, Evans RM, Moore DD. The constitutive androstane receptor and pregnane X-receptor function coordinately to prevent bile acid-induced hepatotoxicity. Journal of Biology and Chemistry 2004; 279(47)49517–49522
   PubMed Web of Science ®Google Scholar
• Zhang L, Fitzloff JF, Engel LC, Cook CS. Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica 2001; 31(2)73–83
   PubMed Web of Science ®Google Scholar
• Zhang S, Qin C, Safe SH. Flavonoids as aryl hydrocarbon receptor agonists/antagonists: Effects of structure and cell context. Environmental Health Perspectives 2003; 111(16)1877–1882
   PubMed Web of Science ®Google Scholar
• Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, Sellers EM. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metabolism and Disposition 2002; 30(3)314–318
   PubMedGoogle Scholar
• Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metabolism and Disposition 2003; 31(6)768–772
   PubMed Web of Science ®Google Scholar
• Zhao P, Kunze KL, Lee CA. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metabolism and Disposition 2005; 33(6)853–861
   PubMed Web of Science ®Google Scholar
• Zhao XJ, Ishizaki T. A further interaction study of quinine with clinically important drugs by human liver microsomes: Determinations of inhibition constant (Ki) and type of inhibition. European Journal of Drug Metabolism and Pharmacokinetics 1999; 24(3)272–278
   PubMedGoogle Scholar
• Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 2002; 32(10)863–878
   PubMed Web of Science ®Google Scholar
• Zhou Q, Yao TW, Yu YN, Zeng S. Concentration dependent stereoselectivity of propafenone N-depropylation metabolism with human hepatic recombinant CYP1A2. Pharmazie 2003; 58(9)651–653
   PubMedGoogle Scholar
• Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Current Drug Metabolism 2004; 5(5)415–442
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clinical Pharmacokinetics 2005; 44(3)279–304
   PubMed Web of Science ®Google Scholar
• Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metabolism and Disposition 2005; 33(4)500–507
   PubMed Web of Science ®Google Scholar
• Zhuo X, Zheng N, Felix CA, Blair IA. Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metabolism and Disposition 2004; 32(9)993–1000
   PubMed Web of Science ®Google Scholar